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Manhiça, Spain, 11th of July 2017 
Dear Editors, 
Please find attached a manuscript entitled “Maternal carriage of Group B 
streptococcus and Escherichia coli in a district hospital in Mozambique”. 
 
This manuscript describes an observational prospective study on carriage of Group B 
streptococcus (GBS) and Escherichia Coli (E. coli) among pregnant women in a 
semirural district in southern Mozambique.  
GBS and E. coli are leading causes of neonatal sepsis in many industrialized countries, 
however, in low-income countries (LIC), data on prevalence and effects of these 
pathogens are scarce. Strategies involving GBS screening during pregnancy, followed 
by intrapartum antibiotic prophylaxis have managed to significantly wipe GBS early 
onset disease in those places where they have been implemented. Unfortunately, the 
fragility of the health system in LIC hinders the applicability of such strategies. A better 
understanding of the specific risk factors that may favor maternal colonization and 
transmissibility to the newborn could contribute to the design of preventive strategies 
for E. coli neonatal disease, and calls for innovative ideas to tackle these vertically 
transmitted infections, which still account for a significant burden of disease in places 
like Mozambique. Trying to address this hypothesis we assessed prevalence of GBS and 
E. coli colonization and factors associated among pregnant women, its effect in 
newborns and acceptability towards diagnostic methods in a semirural Mozambican 
hospital. 
 
All the authors have participated in the study and have agreed upon the submitted 
version of the paper. They concur with the subsequent revisions submitted by the 
corresponding author.  
The material is original and unpublished and has not and will not be simultaneously 
submitted elsewhere so long as it is under consideration by the Pediatric Infectious 
Disease Journal. 
The authors declare that they have no conflict of interest. No material submitted as 
part of the manuscripts infringes existing copyrights, or the rights of a third party.  
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RESPONSE TO THE REVIEWERS: 
Dear Editors, 
  
Many thanks for the positive feedback for our paper “Maternal carriage of Group B 
streptococcus and Escherichia coli in a district hospital in Mozambique”. We also appreciate 
the careful review and constructive insights provided by the reviewers, which have significantly 
contributed to improve the manuscript. Below is a point-by-point response to the reviewers’  
and Editor’s remaining queries.  
 
We look forward to your response.  
Yours sincerely,  
 
 
Dr Lola Madrid 
 
====================================================================== 
In preparing your revised manuscript, please pay attention to the following stylistic points that 
simplify the redactor's work: (1) List the first and last names and academic degrees of all listed 
authors on the Title page; (2) Provide "abbreviated title" for cover (max 55 characters); (3) 
Provide "running head" (max 44 characters); (4) Number all pages of manuscript sequentially, 
the title page being Page 1; (5) Type legends for figures on a separate page, placed after the 
references in the manuscript text. 
RESPONSE: Dear editors, all these points were already included in the previous submitted 
version.  
 
 
 
Responses to Editors/Reviewers
 Reviewer's comments: 
Reviewer #1:  
The authors have made good attempts to answer the previous referees' comments. I think the 
essentials of the paper are as good as they can be, given the difficult circumstances 
surrounding recruitment. However, the paper is still not written in good English, for example 
the sentence "We adjusted the multivariate analysis by gestational age as previous studies 
examining the influence of advancing gestation on GBS colonization have observed (albeit with 
conflicting results), as colonization rates appear to change overtime during pregnancy" is 
scrambled and I think means "We adjusted the multivariate analysis by 
gestational age as previous studies examining the influence of advancing gestation on GBS 
colonization have observed that colonization rates appear to change over time during 
pregnancy". In fact, my interpretation of previous studies is that the colonisation of individuals 
varies, not the overall prevalence, which is consistent with their next sentence "However, no 
associations between gestational age and colonization risk by GBS were found".  
 
RESPONSE: authors have changed the sentence to "We adjusted the multivariate analysis by 
gestational age as previous studies examining the influence of advancing gestation on GBS 
colonization have observed that colonization rates appear to change over time during 
pregnancy" as reviewer has suggested.  
 
The authors refer to 'recto-vaginal swabs' which is unfortunate, as when a single swab is used 
to sample both areas, it is obviously important to sample the vagina first and then the rectum, 
not the other way around (as this would be clinically unacceptable). They should be called -
'vagino-rectal swabs'.  
RESPONSE: authors have reviewed and modified recto-vaginal swabs to vagino-rectal swabs 
throughout the full text 
This aside, the description "For GBS determination, samples included a lower vaginal swab, 
and a recto-vaginal sample, consisting on a brief rotation of the swab through the outer 
sphincter", is not clear. I presume a single swab was used for the vaginal swab. For the vagino-
rectal swab, was this two separate swabs or a single swab (both are clinically acceptable)? And 
were both sampling methods used in all women? (it appears so from comments in the results 
but this should be clearly stated).  
RESPONSE: The reviewer is right, as two swabs were collected in all women. One single swab 
for vaginal sample and one single swab for vagino-rectal sample: taking first vaginal sample. 
We have changed these sentences in the Methods section trying to be clearer:  
“For GBS determination, samples included a lower vaginal swab (vaginal sample), and a 
single swab for the vagino-rectal sample, consisting on a sample of the vagina first and then 
the rectum obtained performing a brief rotation of the swab through the outer sphincter. 
Both kinds of swabs were collected in all women in order to compare the prevalence of GBS 
colonization detected by the two samples”. 
 
The authors say "This study shows GBS and E. coli carriage among near term pregnant women 
is reasonably high in southern Mozambique". What do they mean by 'reasonable'? What 
would be unreasonable? A value judgement is inappropriate here; a simple statements of the 
rates would be more appropriate.  
 
RESPONSE: following reviewer´s recommendation we have removed the word “reasonable”.  
 
"This study has several limitations. Only women attending the MDH (and no other maternities) 
were included, and recruitment was not conducted after working hours, being these potential 
sources of selection bias and limiting the generalization of our results to the whole area" - 
'being these' should be 'these being'. And what do they mean by 'the whole area'? They need 
to be more specific.  
RESPONSE: We have modified, according to the reviewer’s suggestion 'being these' to 'these 
being'. The whole area means the entire district. We have changed this sentence too.  
 
The abbreviation for grams is g, not gr.  
 
RESPONSE: authors have reviewed and modified “gr” to “grams” or “g” throughout the full 
text and tables.  
 
When the authors refer to 'previous abortion', do they mean miscarriage or ToP - or were they 
unable to tell? In which case, 'previous pregnancies ending before 24 weeks' might be clearer. 
RESPONSE: we have included in Definitions, the definition of abortion commonly used in 
previous studies conducted at CISM which is the definition of The National Center for Health 
Statistics, the Centers for Disease Control and Prevention (CDC), and the World Health 
Organization (WHO): Abortion was defined as pregnancy termination prior to 20 weeks' 
gestation or a foetus born weighting less than 500 g.  
 
The paper would benefit from careful proof reading and correction by a good English writer.  
RESPONSE: The manuscript has been reviewed by a native English speaker. 
 The results in figure two would be much easier to assess if the points were clean scattered, or 
shown as vertical histograms. 'Area proportional to number of observations' is unclear - it 
appears to be a lot of circles one on top of another, which does not equate to an area. What is 
the parameter on the y axis? Is it optical density? 
RESPONSE: We have reviewed this comment with our statisticians and they do not consider 
it appropriate to represent this type of distributions as histograms. The scatter plot has the 
problem of the superposition of points when they fall on the same coordinates, and they do 
not allow to see well how many there are. To solve this problem, they have created this 
representation in bubbles, with the size of the bubble proportional to the number of 
observations overlapping on the same coordinates.  In the case of figure 2, most bubbles are 
the same because they represent a single observation, but if the reviewer observes the 
figure of serotype II and III, it can be seen that some bubbles are larger than the rest, 
because they correspond to more observations. Our statisticians have recommended us to 
keep this figure like it had been originally presented because it is the clearest representation 
of the data. We have added the meaning of OD in the footnote and clarification on the 
meaning of 'Area of symbol proportional to number of observations' 
 
 
 
Editor: 
 
abstract 
suggest: methods "Neonatal follow-up..." results: "had IgG antibodies against GBS.." 
RESPONSE: changes in abstract performed as the Editor has suggested. 
 
P3.  
RESPONSE: we have updated number of deaths in 2016 as last estimates have been already 
published.  
line 15. remove "a" "...are leading.." 
RESPONSE: we have removed “a”.  
 
line 24. whats the difference between: preterm  birth and very-low-birth-weight delivery? 
RESPONSE: preterm birth is a live birth <37 weeks of gestational age and very-low-birth-
weight is a birth weight <1500gr. I have removed the word “delivery” trying to be clearer.  
 
line 32 remove "currently proposed" 
RESPONSE: this change has been done. 
 34. suggest: "Maternal GBS carriage during the period closely related to delivery has 
consistently been demonstrated to determine the risk of vertical transmission, and 
thus of ensuing neonatal disease" 
RESPONSE: authors have followed Editor´s suggestion. 
 
43 and 48. "Maternal risk factors associated with higher..." 
and other examples of this later on - change to "associated with" not "associated to" 
 
RESPONSE: we have reviewed the full text and have changed all “associated to” to 
“associated with”.  
 
P4. line 16. change "essentially decimated" to "significantly reduced" 
RESPONSE: change done. 
 
 
P5. line 1. change "This study aimed to determine the prevalence of pregnant women 
colonized by GBS and E. coli attending a semi-rural Mozambican hospital" 
RESPONSE: authors have followed Editor´s suggestion. 
 
P8. 33. intrapartum antibiotics cant be administered to the newborn - please modify text 
 
RESPONSE: this mistake has been corrected. We have removed  “or the newborn”. 
 
P12. 11. "penicillin, ampicillin" review spelling of cotrimoxazole throughout 
RESPONSE: authors have reviewed and modified when necessary spelling of cotrimoxazole 
throughout the full text.  
 
 
P15. 38 "antibodies against GBS" 
RESPONSE: change done. 
 
 
P16. line 22. "intrauterine infection with subsequent negative cultures" 
why? did this mum receive antibiotics before cultures were obtained? 
 RESPONSE: thank you for this comment. This baby was born to an HIV positive mother and 
was taking co-trimoxazole as prophylaxis. We have included the following comment: “This 
mother was HIV positive and was taking co-trimoxazole as prophylaxis of opportunistic 
infections”. 
P17. 41. "....working hours, these being potential sources of selection bias and limiting..." 
 
RESPONSE: RESPONSE: authors have followed Editor´s suggestion. 
 
56. "convenience sample" 
RESPONSE: change done. 
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ABSTRACT 
Background: In low-income countries, data on prevalence and effects of Group 
B streptococcus (GBS) and Escherichia coli (E. coli) colonization among 
pregnant women are scarce, but necessary to formulate prevention strategies. 
We assessed prevalence of GBS and E. coli colonization and factors 
associated among pregnant women, its effect in newborns and acceptability 
regarding the utilized sampling methods in a semirural Mozambican hospital. 
 
Methods: Pregnant women were recruited from June 2014 to January 2015, 
during routine antenatal clinics at gestational age ≥34 weeks (n=200); or upon 
delivery (n=120). Maternal risk factors were collected. Vaginal and vagino-rectal 
samples for GBS and E. coli determination were obtained and characterized in 
terms of antimicrobial resistance and serotype. Anti-GBS antibodies were also 
determined. Neonatal follow-up was performed in the first three months after 
birth. Semi-structured interviews were performed to investigate acceptability of 
sample collection methods. 
Results: 21.3% of women recruited were GBS carriers, while 16.3% were 
positive for E. coli. Prevalence of HIV was 36.6%. No association was found 
between being colonized by GBS and E. coli and maternal risk factors. GBS 
isolates were fully susceptible to penicillin and ampicillin. Serotypes V (32.4%), 
Ia (14.7%) and III (10.3%) were the most commonly found and 69.2% of the 
women tested had IgG antibodies against GBS. E. coli isolates showed 
resistance to ampicillin in 28.9% and trimethoprim/sulfamethoxazole in 61.3% of 
the cases.  
Conclusion: Prevalence of GBS and/or E. coli colonization among pregnant 
women is high in this semirural community and comparable to those reported in 
similar settings. Four serotypes accounted for nearly 70% of all isolates of GBS. 
Population based data on infant GBS infections would enable the design of 
prevention strategies for GBS disease in Mozambique. 
Abstract
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ABSTRACT 
Background: In low-income countries, data on prevalence and effects of Group 
B streptococcus (GBS) and Escherichia coli (E. coli) colonization among 
pregnant women are scarce, but necessary to formulate prevention strategies. 
We assessed prevalence of GBS and E. coli colonization and factors 
associated among pregnant women, its effect in newborns and acceptability 
towards regarding the utilized diagnostic sampling methods in a semirural 
Mozambican hospital. 
 
Methods: Pregnant women were recruited from June 2014 to January 2015, 
during routine antenatal clinics at gestational age ≥34 weeks (n=200); or upon 
delivery (n=120). Maternal risk factors were collected. Vaginal and vagino-
rectalo-vaginal samples for GBS and E. coli determination were obtained and 
characterized in terms of antimicrobial resistance and serotype. Anti-GBS 
antibodies were also determined. Neonatale follow-up was performed in the first 
three months after birth. Semi-structured interviews were performed to know 
investigate acceptability of sample collecting collection methodssamples. 
Results: 21.3% of women recruited were GBS carriers, while 16.3% were 
positive for E. coli. Prevalence of HIV was 36.6%. No association was found 
between being colonized by GBS and E. coli and maternal risk factors. GBS 
isolates were fully susceptible to penicillin and ampicillin. Serotypes V (32.4%), 
Ia (14.7%) and III (10.3%) were the most commonly found and 69.2% of the 
women tested had IgG antibodies againstanti- GBS. E. coli isolates showed 
resistance to ampicillin in 28.9% and trimethoprim/sulfamethoxazole in 61.3% of 
the cases.  
Conclusion: Prevalence of GBS and/or E. coli colonization among pregnant 
women is high in this semirural community and comparable to those reported in 
similar settings. Four serotypes accounted for nearly 70% of all isolates of GBS. 
Population based data on infant GBS infections, would enable the design of 
prevention strategies for GBS disease in Mozambique.  
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BACKGROUND 
In 20156, 5.96 million children under the age of five died with nearly half of 
those deaths occurring in the first 28 days of life, the so-called neonatal period 
(1)d(2). Neonatal deaths are disproportionately distributed across the globe, 
with 95% of them taking place in developing regions and infections remain a 
major contributor to this preventable mortality(2, 3).   
 
Vertical transmission of bacteria that are normal commensal flora or pathogens 
of the maternal genitourinary and gastrointestinal tracts, such as Group B 
streptococcus (GBS) or Escherichia coli (E. coli) are a leading determinants of 
neonatal morbidity and mortality, causing invasive bacterial infections that can 
manifest as sepsis, pneumonia and meningitis(4, 5). GBS and E. coli are 
particularly associated with early-onset neonatal disease (EOD, 0-6 days after 
birth(6)), but can also cause late-onset disease (LOD, 7-89 days(7)), preterm 
birth and very-low-birth-weight delivery(8, 9), all of which are responsible for 
substantial morbidity and mortality in sub-Saharan Africa (SSA)(2, 10, 11).The 
estimated incidence of GBS neonatal disease in SSA countries suggests a 
burden at least comparable to that found in high-income countries (HIC) before 
the implementation of the currently proposed preventive strategies(12). 
 
Maternal GBS carriage during the period closely related to the delivery has 
consistently been demonstrated to determine the risk of vertical transmission, 
and thus of ensuing neonatal ensuing disease. Prevalence of maternal 
colonization varies from 6.5 to 36%(13) in Europe and has been reported higher 
than 20% in Sub-Saharan countries, although precise regional maternal 
carriage data for this continent are scarce(12, 14, 15). Maternal risk factors 
associated towith higher prevalence of GBS colonization are controversial. Both 
younger(16) and older maternal ages(17) have been reported as maternal 
characteristics associated withto higher risk of GBS colonization, as well as 
higher education(17), higher income(18), and high sexual activity(17). The 
relation between HIV infection and risk for GBS maternal colonization has yet to 
be fully elucidated. Studies conducted in the United States(19) or in 
Zimbabwe(15) did not find an increased risk among HIV infected individuals, 
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 4 
whereas researchers from South Africa(20) found a lower colonization 
prevalence among HIV-infected mothers. Vertical transmission of GBS may 
significantly increase (up to a 64% higher) among HIV-exposed infants 
compared with non-HIV exposed ones(12).  
 
The primary intervention to reduce GBS-associated EOD involves the 
administration of intrapartum antibiotic prophylaxis (IAP) to women identified to 
either 1) be GBS carriers through microbiological screening (35-37 weeks’ 
gestation)(21) of samples obtained from their genito-urinary or gastrointestinal 
lower tract; or 2) fulfil any of the different risk factors associated towith neonatal 
disease(22-24). In HIC, the widespread implementation of the IAP strategy has 
significantly reduced essentially decimated GBS EOD among those babies born 
to women in whom it was correctly applied. The IAP strategy has however not 
demonstrated any impact on GBS-associated LOD, or in the prevention of E. 
coli neonatal disease of any kind(12, 13). In low and lower-middle income 
countries (LIC and LMIC), the fragility of the health systems and the generalized 
lack of microbiology facilities, in the absence of a reliable rapid point of care test 
for GBS, hinders the applicability of the IAP strategy, therefore jeopardising the 
prevention of life-threatening GBS neonatal infections(12). 
Despite SSA having the highest incidence of neonatal sepsis worldwide(12), 
epidemiological data on GBS and E. coli maternal colonization in this continent 
are scarce. In Mozambique, as a paradigmatic example, a Pubmed search only 
provides five results from studies reporting GBS data(12, 25-28), and only two 
of those related to maternal colonization, describing a prevalence of 
colonization as low as 1.8%(25) or even lower (1%)(27), difficult to contextualize 
among much higher prevalence data from neighboring sub-Saharan African 
countries(12). Additionally, and to our knowledge, no articles reporting E. coli 
colonization prevalence in pregnant women in Mozambique have been 
published and only one multicenter study conducted in South Africa, Kenya and 
Rwanda have determined simultaneously the vaginal GBS and E. coli carriage 
rates in SSA(29, 30). Such data, however, appear necessary for a better and 
more evidence-based design of preventive strategies, based on the resources 
and infrastructures available. 
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 5 
This study aimed to determine the prevalence of pregnant women colonized 
pregnant women by GBS and E. coli attendinged in a semi-rural Mozambican 
hospital, analyze risk factors associated to higher risk of carriage by these 
pathogens and characterize the isolates in terms of antimicrobial resistance and 
serotype distribution. As secondary objectives, we determined the neonatal 
outcomes and assessed the feasibility and acceptability of collecting vaginal 
and recto-vaginalvagino-rectal samples among pregnant women, with the idea 
of generating locally-relevant data evidence useful to guide national preventive 
strategies and policies to reduce transmission and the toll of such potentially 
life-threatening infections in the newborn.  
 
 
METHODS 
Study site 
The study was conducted in Manhiça, a semi-rural site in Southern 
Mozambique. The Manhiça Health Research Center (CISM) runs a 
Demographic Surveillance System (DSS) in the area and a morbidity 
surveillance system (MSS) at the Manhiça District Hospital (MDH), across the 
street. A detailed description of MDH, CISM and the study area can be found 
elsewhere(31). MDH is the referral hospital for the Manhiça district, covering a 
population of circa 183,000 inhabitants.  The MDH includes adult and paediatric 
wards, together with a maternity, where between 3500-4000 deliveries take 
place annually. Institutional delivery rates is are around 85-90% in the study 
area. It MDH also includes an outpatient department and an antenatal care 
(ANC) clinic where pregnant women are routinely followed. As part of the 
National policy, all pregnant women are invited to attend antenatal consultations 
during their pregnancy, where HIV testing and other screening of infections and 
conditions are routinely offered, in addition to intermittent preventive treatment 
during pregnancy (IPTp) for malaria prevention, a disease highly endemic in the 
area. Manhiça district has one of the highest prevalence rates of HIV in the 
world, with HIV prevalence during pregnancy having been estimated at around 
29% during antenatal consultations(32). No strategy to prevent neonatal sepsis 
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 6 
is currently implemented in Mozambique. The hospital has recently introduced 
WHO-recommended Option B+ for the prevention of mother-to-child HIV 
transmission, which is offered to mothers free of charge. 
 
Study design and population. 
This observational prospective study was conducted at the ANC and delivery 
wards of MDH, between June 15 2014 and January 15 2015, running 
continuously during working hours (8:00–16:00) and working days. We recruited 
pregnant women at two different time-points during their pregnancy. One group 
during routine antenatal care with a minimum estimated gestational age ≥34 
weeks, as measured by fundal height >=32cms, 2 cms above the midpoint 
between umbilicus and xiphoyd process. A second group of women was 
recruited upon delivery (regardless of gestational age) if they were not recruited 
at ANC clinics, in order to understand real life risk for vertical transmission rate 
of GBS or E. coli to their offspring with no interference of antibiotic treatments. 
Participants were eligible for inclusion if they lived in the study area, were in 
good physical and mental health, able and willing to participate in the study and 
to provide informed consent. All women fulfilling inclusion criteria were eligible 
to participate in the study, and in order to obtain a more representative sample 
of the study population, the first two women seen every day were approached 
for recruitment. 
 
Definitions 
GBS colonization was considered in the event of a positive vaginal or recto-
vaginalvagino-rectal culture for GBS. E. coli colonization was considered when 
the positive vaginal culture grew E. coli. E. coli urinary tract infection was 
diagnosed when E. coli grew (>105 colony-forming units/mL) in the urine 
samples of pregnant women. Abortion was defined as pregnancy termination 
prior to 20 weeks' gestation or a foetus born weighting less than 500 g(33). A 
preterm baby was defined as that with a gestational age at birth <37 weeks and 
stillbirth as intrauterine deaths occurring after 28 weeks of gestational age. Low-
birth weight was defined as weight at birth <2,500 grams.  
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 7 
Study procedures 
Sampling procedures 
Microbiological swab samples were obtained from each participant (ANC or 
upon admission in labour at the delivery wards, but always prior to delivery) 
without the use of antiseptic solution or a speculum. A sample from the lower 
third of the vagina and a fresh urine sample were taken for E. coli 
determination. For GBS determination, samples included a lower vaginal swab 
(vaginal sample), and a single swab for the vagino-rectal sample, consisting on 
a sample of the vagina first and then the rectum obtained performing a brief 
rotation of the swab through the outer sphincter. Both kinds of swabs were 
collected in all women in order to compare the prevalence of GBS colonization 
detected by the two samplesFor GBS determination, samples included a lower 
vaginal swab (vaginal sample), and a single swab for recto-vaginalvagino-rectal 
sample, consisting on a sample of the vagina first and then the rectum through 
a brief rotation of the swab through the outer sphincter. Both kinds of swabs 
were collected in all women in order to compare the prevalence of GBS 
colonization detected by the two samples. Swabs were immediately placed in 
Amies transport medium and sent to the laboratory within 24 hours. The vaginal 
and recto-vaginalvagino-rectal samples for GBS determination were inoculated 
directly onto Granada medium (Group B Streptococcus Differential Agar, 
Becton Dickinson, Erembodegem, Belgium) incubated anaerobically at 37ºC for 
24 hours. Vaginal samples for E. coli determination were spread onto 
MacConkey agar and urine samples were inoculated onto agar Cysteine lactose 
electrolyte deficient (CLED) and MacConkey agar and incubated at 37ºC 
overnight without C02. E. coli isolates were identified based on colony 
appearance, Gram stain, latex agglutination with the Pastorex Strepto kit (Bio-
rad Laboratories®, Marnes-la-Coquette, France) and standard biochemical 
tests for E. coli determination. Both, GBS and E. coli isolates were confirmed by 
MALDI-TOF. Resistance profiles were determined via Kirby-Bauer disk diffusion 
method following the Clinical & Laboratory Standards Institute (CSLI) 
guidelines.  
Determination of the GBS capsular type or serotype implied the utilization of a 
multiplex-PCR using a set of primers described previously(34). DNA of each 
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 8 
isolate was obtained using the High Pure PCR Template Preparation kit 
(Roche, Spain). Briefly, this procedure consisted in performing three PCR 
reactions using specific primers for 10 different serotypes. Reaction 1 detects 
[Ia, Ib, II, III and IV], reaction 2 [V, VI, VII, VIII and IX] and reaction 3 is the 
amplification control. PCR conditions involved an initial step of 95ºC for 3 min, 
followed by 30 cycles of 95º C for 1 min, 57º C for 1 min and 72º C for 2 min, 
and a final step of 72º C for 10 min The PCR products were visualized by 
electrophoresis using 1% agarose gels. Antibody (AB) determination was 
identified in blood samples of mothers recruited at delivery. They were 
performed by ELISA using whole bacteria as antigens. This procedure is a 
modification based on the protocol proposed by Baker et al (33), using an 
optical density to 450 nm with a correction at 620 nm. The cut-off value for 
positivity was chosen to be ≥ 1 OD units, in order to be more strict than the one 
proposed by Baker (>0.125). 
Maternal HIV infection status was determined and recorded if not previously 
known. Other screening tests routinely performed at ANC, such as syphilis or 
hemoglobin determination were also performed and recorded.  
 
Communication of results to mothers and case management 
Clinical assessment and management of patients was done following 
international guidelines for countries with no clear screen-and-treat national 
rules, both at the ANC and at the maternity. For those women identified as 
carriers of GBS in recto-vaginalvagino-rectal swabs collected at the ANC, a field 
worker delivered to the mother at home a study card detailing the 
microbiological findings, together with indications of what to do during delivery, 
so that intrapartum antibiotics could be administered to the mother or the 
newborn  , according tofollowing the CDC guidelines(35). Urinary tract 
infections secondary to E. coli were also reported and treated according to 
national guidelines for pregnant women. All recruited women were encouraged 
to deliver at hospital and clinical staff was trained to identify them. Any child 
born to a recruited mother and found to be sick at delivery was assessed by a 
study clinician, and routine screening for bacterial surveillance (including a 
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 9 
blood culture and a lumbar puncture to obtain cerebrospinal fluid (CSF)) 
performed and clinical management organized according to MDH guidelines. 
Although the aim of this study was not to assess the efficacy of IAP (already 
known), due to ethical considerations, IAP was started in GBS infected women 
upon labour initiation, according to CDC guidelines(35). In cases where IAP 
could not be adequately performed, we followed Spanish recommendations and 
prophylactic antibiotic treatment (50,000 IU of intramuscular penicillin as a 
single dose for a newborn weighting >2000 grams, or 25.000 IU if weight <2000 
grams) was administered within the first hour after birth to the newborns of 
mothers with confirmed GBS colonization(36). Such children were observed at 
hospital for a minimum of 24h. For women recruited at delivery, culture results 
were not available until at least 24-48h after recruitment. In such cases (and 
also in cases of women with pending GBS result recruited prior to delivery) we 
kept the newborns under observation for a minimum of 24 hours after delivery, 
and provided clear recommendations to mothers regarding the need for a follow 
up visit should the newborn become sick in the first weeks of life. Babies born to 
study participant mothers were followed-up during the first three months after 
birth.  
 
Assessment of the acceptability of vaginal and recto-vaginalvagino-rectal 
sampling 
The study included a simple socio-behavioural component to evaluate the 
acceptability of collecting samples (vaginal and recto-vaginalvagino-rectal 
swabs) during pregnancy. "Non-participant observations" were conducted, 
whereby a member of the study team observed the procedures being 
conducted (excluding genital examinations), and complemented by semi-
structured interviews to a small sample of pregnant women not participating in 
the study but contemporaneously attending the ANC. Finally, semi-structured 
interviews were conducted among some participants who had accepted to 
provide vaginal and rectal samples. Questions, themes and probes arising from 
the non-participant observation, other than stated in the interview guide, were 
included in the semi-structured interviews. 
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Statistical analysis 
All data were prospectively collected using standardized questionnaires, which 
were double entered in specific study databases, created using Openclinica© 
software. Discrepancies were solved after comparison with the original source 
documents by a senior data clerk, and in close collaboration with the study 
clinicians. Statistical analyses were performed using StataCorp. 2015. Stata 
Statistical Software: Release 14 (College Station, TX: StataCorp LP). Study 
variables were counted and summarized in frequency tables. Qualitative 
variables were compared using a Chi-squared test or Fisher’s exact test. 
Continuous variables were described as mean (standard deviation, SD) or 
median values (interquartile range, IQR) and were compared using the t test for 
normal distributions or the Mann Whitney test for skewed data. Logistic 
regression univariate and multivariate analyses were performed to identify risk 
factors for GBS or E. coli colonization, separately. Variables that were found to 
be significantly associated with GBS or E. coli in the univariate analysis together 
with those related at a significance level of p<0.10 were entered into a 
multivariate model. Age and gestational age at recruitment were also included 
in the multivariate analysis based on previous studies(9, 15-17). A separate 
univariate and multivariate analysis of risk factor associated to GBS or E. coli 
colonization among HIV pregnant women was also performed. 
Ethical considerations 
This protocol and all supporting documentation (Informed consent documents, 
Study questionnaires) were approved by the local bioethics committee of CISM 
(Comité Institucional de Bioética para Saúde do CISM (CIBS-CISM)), and by 
the National Bioethics Committee of Maputo (CNBS) in Mozambique; and by 
the Ethics Committee of the Hospital Clínic in Barcelona, Spain. Written 
information and consent forms in the local language were provided to the 
women. After the interview, participants were asked to express their willingness 
to participate in the study by signing (or thumb-printing in case they were 
illiterate) the consent form. Participation in this study was voluntary, and study-
related procedures did not interfere with the pregnant women’s or children’s 
standard clinical care. 
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RESULTS 
Between June 15 2014 and January 15 2015, 320 pregnant women were 
recruited at MDH (Study profile in figure 1). Table 1 summarizes the socio-
demographic and clinical characteristics of participants. Median age of recruited 
women was 24 years (Interquartile range, IQR 20-31), with no significant 
differences according to recruitment place. No major differences could be found 
in relation with recruitment site, with the exception of a higher frequency of 
higher education among women recruited upon delivery compared with those 
recruited at ANC (7.0% vs. 26.7%, p<0.001). More than one third of women 
(117/320, 36.6%) were HIV positive.  
Prevalence of GBS and E. coli colonization among pregnant women 
More than a fifth (68/320; 21.3%) of all recruited women was were colonized by 
GBS, detected in both samples in 33 women, in 15 in the vaginal one only, and 
in 20 in the recto-vaginalvagino-rectal one only. A non-statistically significant 
higher proportion of GBS were isolated from the recto-vaginavagino-rectal 
sample (16.6%) as compared to the vagina (15.0%, p=0.81). Prevalence of 
GBS colonization was borderline significantly higher among women recruited 
upon delivery compared to those recruited at ANC (32/120 (26.7%) vs. 36/200 
(18.0%), p=0.07).  Fifty-two women had E. coli vaginal colonization (16.3%), 
being significantly more common among women recruited at delivery (22.5% vs. 
12.5%, p=0.019) and 10/320 (3.1%) had a positive E. coli urine culture. Among 
HIV positive pregnant women recruited, GBS colonization was found in 26/117 
(22.2%). E. coli vaginal colonization was determined in 18/117 (15.4%) HIV-
positive women. 
Anti-group B streptococcus antibodies 
Antibodies against GBS were detected in 83/120 (69.1%) women recruited at 
delivery. Of them, 23/32 (71.9%) were among GBS colonized mothers and 
60/88 (68.2%) among non-colonized women (figure 2). Among HIV positive 
participants, AB anti-GBS were detected in 25/38 (65.8%) of those tested. Forty 
women had AB against more than one GBS serotype, being the most frequent 
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AB against serotype Ia (24/120, 20%), against serotype Ib (76/120, 63.3%) and 
against serotype V (27/120, 22.5%). Correlating presence of antibodies to the 
homotypic GBS serotype, 2/4 (50%) women colonized by serotype Ia had AB 
against it, 6/6 (100%) for serotype Ib, 0/3 (0%) for serotype III and 7/14 (50%) of 
those carriers of Ib serotype had AB against their homotypic serotype. 
Risk factors associated to GBS and E. coli carriage 
Table 2 presents the univariate analyses of associations of the different socio-
demographics, clinical and laboratory variables with vaginal GBS and E. coli 
carriage. In the final multivariate GBS model (Table 3), no risk factors were 
significantly associated with GBS carriage. Similarly, no risk factors appeared to 
be independently associated with maternal vaginal E. coli carriage (table 4). 
The univariate and multivariate analyses performed to identify risk factors of 
GBS or E. coli colonization but restricted to HIV-infected women showed no 
differences compared to those including all women (data not shown). 
Antimicrobial susceptibility and serotyping 
One hundred and one specimens were found to be positive for GBS (48 vaginal 
and 53 recto-vaginalvagino-rectal). All GBS isolates were fully sensitive to 
penicillin, ampicillin and ceftriaxone. Thirty-four (32.7%) isolates were resistant 
to erythromycin and 20 (19.2%) isolates to clindamycin. Seven isolates showed 
erythromycin-induced resistance to clindamycin.  All the E. coli isolates were 
screened for susceptibility to 18 antimicrobial agents. Susceptibility to all 
antimicrobial agents tested was seen in 14 isolates (22.6%).  E. coli was 
resistant to ampicillin in 21 (38.9%) cases, ceftriaxone in 2 (3.2%) cases, 
amoxicillin/clavulanate acid in 12 cases (19.4%), ciprofloxacin in 4 cases (6.5%) 
and co-trimoxazole in 38 cases (61.3%). Figure 3 summarizes the distribution of 
antimicrobial resistance (classifying isolates showing intermediate levels of 
susceptibility as resistant). Details of the resistance profiles of GBS and E. coli 
isolates are shown in Supplementary material table S1. 
The serotype distribution of the GBS isolates is presented in Fig 4 and Fig S1 in 
the Supplementary material. The most prevalent serotypes were V (32.4%), Ia 
(14.7%), III and Ib (10.3% and 8.8%, respectively). Sixteen isolates (23.5%) 
were non-typeable. Twenty-six women had the same serotype detected both in 
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the vaginal and recto-vaginalvagino-rectal swabs, while in seven cases 
infections were serotype-discordant.  
 Neonatal outcomes 
Three hundred and twenty neonatal outcomes from 316 pregnant women were 
recorded (98.8%). The Deliveries delivery outcomes of four women in the ANC 
group were not registered at MDH. Neonatal outcomes included four pair of 
twins, 290 term babies, 25 preterm and 5 cases of stillbirths. Figure 1 illustrates 
neonatal outcomes and follow-up in detail. Characteristics of neonates born of 
mothers participating in the study may be found in table 1 and 2. Thirty-two 
neonates born of 36 (88.9%) GBS carriers recruited at ANC were born at MDH, 
and 4 outside of the health system. Due to lack of qualified clinical staff, work 
saturation and advanced stage of labor, IAP strategy as recommended by 
CDC(35) was  feasible only in two known GBS carriers at time of delivery, we 
administered a single dose of penicillin to 22 neonates in the first hour after 
birth.. Two hundred and sixty-two infants (81.9%) were followed-up until 90 
days of age and 8/262 (3.1%) were admitted in the hospital during this period. 
Seven infants died among those followed-up until 3 months after birth (2.7%), 
being five of them HIV-exposed (one clinical sepsis, one perinatal asphyxia and 
3 unknown causes). A significantly higher risk for death among those neonates 
born of mothers recruited at ANC compared to those recruited at delivery (3.6% 
vs. 1.7%, p<0.001) was found.  
 
Acceptability of vaginal and recto-vaginalvagino-rectal sampling 
Fifteen study participant women and five non-study pregnant women were 
recruited for the social component. Acceptability of collecting vaginal and recto-
vaginalvagino-rectal samples was 100%. Facilitators for acceptance included: 
a) Willingness to know whether they had a reproductive tract infection; b) Being 
interested in understanding the objectives of collecting vaginal and recto-
vaginalvagino-rectal samples; and c) Willingness to be treated and 
accompanied to the hospital in case of reproductive tract infection and avoiding 
transmitting them to their offsprings. Only a few women felt uncomfortable with 
sample collection, referring to feeling of burning and/or pain. Although all 
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participants of the social component accepted sample collection, possible 
barriers for acceptance of future recto-vaginalvagino-rectal sample collection 
were explored and these included: a) fear in relation to the first time being 
submitted to this procedure; b) worries regarding being seen at the hospital 
(stigma); c) lack of privacy at the ANC at time of sample collection. 
 
DISCUSSION 
To our knowledge, this is the first study presenting data on GBS maternal 
colonization, antibodies againstnti- GBS and characterization of isolates in a 
rural area of Mozambique and the first time concomitantly examining E. coli 
colonization in pregnant women in the country. Maternal rate of GBS 
colonization found in this study, 21.3%, was as high as previous work in other 
countries in Sub-Saharan Africa reported(12). However, two previous studies 
performed in the capital of Mozambique, Maputo, reported an extremely low 
prevalence of GBS colonization among pregnant women of 1% in 1995(27) and 
1.8% in 2008(25). Smaller sample sizes, different study population, and very 
likely laboratory and microbiology procedures utilized for GBS detection, may all 
contribute to explain the significant increase in terms of overall prevalence 
found in our study. Our findings are in close agreement with a systematic review 
on GBS disease in sub-Saharan Africa(12), which included 18 studies reporting 
data on maternal GBS colonization, finding an average GBS carriage of 21.8% 
(95% CI: 18.3 - 25.5) among pregnant women across the region. These results 
are also similar to general prevalence data from other regions, including the 
United States(9) and Europe(13), or from other neighboring countries in Sub-
Saharan Africa such as South Africa (with similar prevalence of HIV(20, 37, 38), 
Zimbabwe(15) or Malawi(39), supporting the credibility of these data. The yield 
of recto-vaginalvagino-rectal sampling was better for GBS colonization than 
using only vaginal samples as previously reported(40, 41) and 
recommended(35).   
No risk factors independently associated with higher prevalence of GBS 
colonization were found in this study. We adjusted the multivariate analysis by 
gestational age as previous studies examining the influence of advancing 
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gestation on GBS colonization have observed (albeit with conflicting results), as 
that colonization rates appear to change overtime during pregnancy(15, 42, 43). 
However, no associations between gestational age and colonization risk by 
GBS were found. Colonization prevalence was similar among age groups, in 
contrast to what has been described by some studies(16, 17, 44) but in 
concordance to a recent multicenter study performed in African settings(37), 
reinforcing the idea that colonization rates are quite stable across a wide variety 
of African settings. We did not find higher education to be a risk factor for GBS 
colonization as other studies have reported(18), a finding possibly influenced by 
the homogeneity of lower education backgrounds in our setting. Importantly, this 
study further contributes to expose the fact that current understanding on 
maternal risk factors for colonization is incomplete. 
No increased risk of GBS colonization among HIV-infected women was found in 
this study, a finding supported by other studies in USA and Zimbabwe(15, 19). 
However, a South African study reported that maternal GBS carriage was lower 
in HIV-positive women and among those with lower CD4 counts in Malawi(20, 
39). This fact could be related to the fact that GBS carriage is inversely 
associated with the use of prophylactic co-trimoxazole among HIV-infected 
women. Information about co-trimoxazole use in this study was not recorded but 
due to high prevalence of HIV in our cohort it is likely that a high proportion of 
participants were routinely taking co-trimoxazole. Although HIV appears not to 
be a risk factor for maternal colonization during pregnancy, a recent South 
African study found that incidence of GBS neonatal disease may be up to 64% 
higher among HIV-exposed infants compared with non-HIV exposed ones(12). 
As of today, no data are available regarding incidence of neonatal GBS invasive 
disease and HIV co-infection in Mozambique. However, studies conducted in 
South Africa(20, 45), with a similar HIV prevalence to the one reported in 
southern Mozambique(32), found an incidence of GBS invasive disease among 
infants higher than that reported in other resource-constrained settings(44, 46). 
Hence, it would appear reasonable to expect a high incidence of GBS invasive 
disease in this particularly HIV-struck study area. However, a low incidence of 
GBS invasive cases in neonates born to GBS infected women was found in this 
study. Reasons for this low incidence could be the high prevalence of 
antibodies againstnti -GBS found in the studied cohort (69.2%). Maternal 
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antibody levels have been associated with protection against invasive GBS 
disease in high(47) and lower-middle income settings(48) and it has been 
documented that againstanti- GBS placental transfer is appears not to benot 
affected by HIV infection(49). It is difficult to correlate our againstnti- GBS AB 
results with what is known regarding GBS maternal colonization and infant 
disease. The highest proportion of women with anti-GBS AB wasere against 
serotype Ib, Ia and V, consistent with predominant serotypes among carriers in 
our cohort. Although we did not examine antibody correlation between mothers 
and newborns, the higher prevalence of antibodies in our cohort could also 
potentially explain this low incidence of GBS invasive disease among our 
neonate cohort. In addition, prevalence of carriers of serotype III in this 
population, the known serotype causing more infant invasive disease(50), was 
lower than reported in other African studies(12), which would be also consistent 
with a lower incidence among infants. Another reason could be the attempt to 
implement IAP strategy to those colonized GBS mothers delivering at MDH. 
None of the neonates who received a single dose of penicillin after birth 
developed symptoms of sepsis. Understanding that this strategy is not generally 
recommended on account of the risks of enhancing antimicrobial resistance, 
and in spite of the small sample, it could be argued that for settings were 
access to health is problematic, but where GBS maternal carriage can be 
confirmed, such a strategy could prove effective in decreasing neonatal early 
morbidity by blocking the infection’s transmissibility at a moment where the 
baby is still under the surveillance of the health system. The only GBS case in 
our study was a newborn developing symptoms in the first 24 hours, born to a 
mother recruited at delivery with negative GBS screening. This mother was HIV 
positive and was taking co-trimoxazole as prophylaxis of opportunistic 
infections, suggesting an intrauterine infection with a subsequent negativization.  
 
On the other hand, the prevalence of E. coli found in this study was lower than 
reported from other authors in different African settings(20, 37) but comparable 
with the prevalence reported by Karou in Togo(51). No risk factors were found 
to be independently associated with a higher risk of E. coli vaginal carriage 
among pregnant women. Some studies have reported specific risks factors for 
E. coli colonization, including sexual practices such as anal intercourse during 
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pregnancy(52) or being a sexual worker(37). Such factors were however not 
explored in our study.  
Importantly, GBS continues to be susceptible to penicillin, ampicillin, and 
ceftriaxone in this setting. Previous studies in Ethiopia(53, 54) and South 
Africa(18, 51) also reported full susceptibility of GBS strains to penicillin. Rarer 
cases of decreased susceptibility to penicillin have been reported in Japan and 
the United States(55). A study in Zimbabwe found almost 100 % of isolates 
sensitive to penicillin, with 2% showing intermediate susceptibility to penicillin.  
Resistance to erythromycin resistance among invasive GBS isolates in Europe 
ranges from 3.8% to 21.2%(13) and from 7% to 25% in the USA and 
Canada(24). Higher levels of resistance to erythromycin (~33%) were found in 
this study which could be related to mass drug administration (MDA) of 
azithromycin for trachoma control in sub-Saharan Africa since development of 
macrolide-resistant pathogens after more than one round of mass treatment has 
already reported(56, 57). Erythromycin resistance is frequently associated with 
clindamycin resistance(24). The emergence of non-susceptible GBS strains has 
important public health implications. GBS is still susceptible to penicillin and 
ampicillin which are the antibiotics of choice. Erythromycin and clindamycin are 
the drugs of choice for penicillin-hypersensitive patients and resistance to these 
antibiotics is emerging.  
As other studies have reported(12), serotypes Ia, Ib, II, III and V were 
predominant. However, the most frequent serotype (V) found in this study 
differs from those found in the majority of studies conducted in other countries, 
revealing the need to identify prevalent serotypes in each region, as a 
prerequisite of establishing the potential coverage, impact and implementation 
requirements of future anti GBS vaccination strategies.  
Characterization of E. coli isolates from this study has been described by Saez 
et al(58). E. coli isolates showed significant resistance to co-trimoxazole, as a 
previous study on diarrhoeagenic E. coli(59) conducted in Manhiça already 
described. Reasons for such high SXT resistance levels may include its 
extensive use as treatment of community-acquired infections, or as prophylaxis 
of HIV-related opportunistic infections(60).  
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This study has several limitations. Only women attending the MDH (and no 
other maternities) were included, and recruitment was not conducted after 
working hours, being these being  potential sources of selection bias and 
limiting the generalization of our results to the whole entire districtarea. The first 
two women fulfilling inclusion criteria every day were invited to participate in the 
study, leading to only 200 women being recruited at ANC, and 120 additional 
ones upon delivery, an estimated 10% of all deliveries per year attended at 
MDH. Pregnant women are less likely to attend ANC at the end of their 
pregnancies, and some women who attend antenatal care in other maternities 
do actually choose MDH to deliver. Altogether this justifies our sampling 
strategy, but it is important to highlight that this convenience convenient sample 
may not be truly representative of the entire pregnancy cohort in the area. We 
did not collect information about population not sampled and we were unable to 
compare it with our population in order to assess such potential selection bias. 
However, the maternity at MDH is the biggest one in the study area and women 
seen there come from different places of the district and a sample of women 
attended at delivery was also recruited, minimizing bias. Other studies have 
reported association of other sexually transmitted infections such as gonorrhea 
or bacterial vaginosis(37) or socio-economic status(44) with GBS colonization in 
pregnant women, but we did not measure these variables. However, an attempt 
was made to explore the majority of potential risk factors described by other 
authors. Finally, and albeit this not being an objective of the study, it was 
impossible to assess the risk of GBS and E. coli transmission in this cohort, due 
the lack of denominator.  
 
Conclusion 
This study shows GBS and E. coli carriage among near term pregnant women 
is reasonably high in southern Mozambique. HIV infection was not a risk factor 
for GBS or E. coli colonization. Presence of anti-GBS antibodies, administration 
of single dose of penicillin to neonates born to colonized mothers or use of 
prophylactic co-trimoxazole among HIV-infected pregnant women could be 
reasons to explaining the low incidence of GBS invasive disease among our 
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cohort of newborns.  
Screening mothers near term and providing appropriate antimicrobial 
prophylaxis could prevent potential adverse neonatal outcomes. Unfortunately, 
the fragility of the health system in LIC hinders the applicability of such 
approaches, and calls for innovative ideas to tackle these vertically transmitted 
infections. Serotype V was the most prevalent in our community and four 
serotypes cause the majority of cases of GBS colonization. The development 
and implementation of a conjugate vaccine incorporating the most commonly 
found serotypes globally, could enhance the transfer of maternal antibodies to 
the baby and protect their health in those critical first moments for survival. 
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LEGENDS FOR FIGURES 
Figure 1.  Study profile. 
ANC: antenatal clinics; IC: informed consent; IAP: intrapartum antibiotic 
prophylaxis. MDH: Manhiça district hospital. ˠMicrobiologically not confirmed. 
ᶤNone received any kind of prophylaxis; ʶneonate died before taking samples.ʱ 
GBS sepsis without meningitis developed in the first 24h of life. 
 
Figure 2.  Bubble plot demonstrating antibody antibodies against GBS serotype 
Ia, Ib, II, III, IV and V in blood samples from women recruited at delivery 
(n=120).  
  OD: optical density to 450 nm with a correction at 620 nm. Cut-off value for 
positivity was ≥ 1 OD units. 
 
Figure 3. Distribution of antimicrobial resistance among GBS and E. coli 
isolates 
PEN, penicillin; AMP, ampicillin; CTX, ceftriaxone; ERY: erythromycin; CD, 
clindamycin; TET, tetracycline;  VA, vancomycin; NAL, nalidixic acid; AMC, 
amoxicillin/clavulanic acid; CXM, cefuroxime,;  FOX, cefoxitine; CAZ, 
ceftazidime; AZT, aztreonam; TZP, piperacillin/tazobactam; ETP, ertapenem; 
IPM, imipenem; MEM, meropenem; CIP, ciprofloxacin; GEN, gentamicin; SXT, 
trimethoprim/ sulfamethoxazole; TOB, tobramycin 
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Maternal carriage of Group B streptococcus and Escherichia coli in a 
district hospital in Mozambique 
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ABSTRACT 
Background: In low-income countries, data on prevalence and effects of Group 
B streptococcus (GBS) and Escherichia coli (E. coli) colonization among 
pregnant women are scarce, but necessary to formulate prevention strategies. 
We assessed prevalence of GBS and E. coli colonization and factors 
associated among pregnant women, its effect in newborns and acceptability 
regarding the utilized sampling methods in a semirural Mozambican hospital. 
 
Methods: Pregnant women were recruited from June 2014 to January 2015, 
during routine antenatal clinics at gestational age ≥34 weeks (n=200); or upon 
delivery (n=120). Maternal risk factors were collected. Vaginal and vagino-rectal 
samples for GBS and E. coli determination were obtained and characterized in 
terms of antimicrobial resistance and serotype. Anti-GBS antibodies were also 
determined. Neonatal follow-up was performed in the first three months after 
birth. Semi-structured interviews were performed to investigate acceptability of 
sample collection methods. 
Results: 21.3% of women recruited were GBS carriers, while 16.3% were 
positive for E. coli. Prevalence of HIV was 36.6%. No association was found 
between being colonized by GBS and E. coli and maternal risk factors. GBS 
isolates were fully susceptible to penicillin and ampicillin. Serotypes V (32.4%), 
Ia (14.7%) and III (10.3%) were the most commonly found and 69.2% of the 
women tested had IgG antibodies against GBS. E. coli isolates showed 
resistance to ampicillin in 28.9% and trimethoprim/sulfamethoxazole in 61.3% of 
the cases.  
Conclusion: Prevalence of GBS and/or E. coli colonization among pregnant 
women is high in this semirural community and comparable to those reported in 
similar settings. Four serotypes accounted for nearly 70% of all isolates of GBS. 
Population based data on infant GBS infections would enable the design of 
prevention strategies for GBS disease in Mozambique.  
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BACKGROUND 
In 2016, 5.6 million children under the age of five died with nearly half of those 
deaths occurring in the first 28 days of life, the so-called neonatal period (1). 
Neonatal deaths are disproportionately distributed across the globe, with 95% of 
them taking place in developing regions and infections remain a major 
contributor to this preventable mortality(2, 3).   
 
Vertical transmission of bacteria that are normal commensal flora or pathogens 
of the maternal genitourinary and gastrointestinal tracts, such as Group B 
streptococcus (GBS) or Escherichia coli (E. coli) are leading determinants of 
neonatal morbidity and mortality, causing invasive bacterial infections that can 
manifest as sepsis, pneumonia and meningitis(4, 5). GBS and E. coli are 
particularly associated with early-onset neonatal disease (EOD, 0-6 days after 
birth(6)), but can also cause late-onset disease (LOD, 7-89 days(7)), preterm 
birth and very-low-birth-weight(8, 9), all of which are responsible for substantial 
morbidity and mortality in sub-Saharan Africa (SSA)(2, 10, 11).The estimated 
incidence of GBS neonatal disease in SSA countries suggests a burden at least 
comparable to that found in high-income countries (HIC) before the 
implementation of the preventive strategies(12). 
 
Maternal GBS carriage during the period closely related to the delivery has 
consistently been demonstrated to determine the risk of vertical transmission, 
and thus of ensuing neonatal disease. Prevalence of maternal colonization 
varies from 6.5 to 36%(13) in Europe and has been reported higher than 20% in 
Sub-Saharan countries, although precise regional maternal carriage data for 
this continent are scarce(12, 14, 15). Maternal risk factors associated with 
higher prevalence of GBS colonization are controversial. Both younger(16) and 
older maternal ages(17) have been reported as maternal characteristics 
associated with higher risk of GBS colonization, as well as higher 
education(17), higher income(18), and high sexual activity(17). The relation 
between HIV infection and risk for GBS maternal colonization has yet to be fully 
elucidated. Studies conducted in the United States(19) or in Zimbabwe(15) did 
not find an increased risk among HIV infected individuals, whereas researchers 
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 4 
from South Africa(20) found a lower colonization prevalence among HIV-
infected mothers. Vertical transmission of GBS may significantly increase (up to 
a 64% higher) among HIV-exposed infants compared with non-HIV exposed 
ones(12).  
 
The primary intervention to reduce GBS-associated EOD involves the 
administration of intrapartum antibiotic prophylaxis (IAP) to women identified to 
either 1) be GBS carriers through microbiological screening (35-37 weeks’ 
gestation)(21) of samples obtained from their genito-urinary or gastrointestinal 
lower tract; or 2) fulfil any of the different risk factors associated with neonatal 
disease(22-24). In HIC, the widespread implementation of the IAP strategy has 
significantly reduced GBS EOD among those babies born to women in whom it 
was correctly applied. The IAP strategy has however not demonstrated any 
impact on GBS-associated LOD, or in the prevention of E. coli neonatal disease 
of any kind(12, 13). In low and lower-middle income countries (LIC and LMIC), 
the fragility of the health systems and the generalized lack of microbiology 
facilities, in the absence of a reliable rapid point of care test for GBS, hinders 
the applicability of the IAP strategy, therefore jeopardising the prevention of life-
threatening GBS neonatal infections(12). 
Despite SSA having the highest incidence of neonatal sepsis worldwide(12), 
epidemiological data on GBS and E. coli maternal colonization in this continent 
are scarce. In Mozambique, as a paradigmatic example, a Pubmed search only 
provides five results from studies reporting GBS data(12, 25-28), and only two 
of those related to maternal colonization, describing a prevalence of 
colonization as low as 1.8%(25) or even lower (1%)(27), difficult to contextualize 
among much higher prevalence data from neighboring sub-Saharan African 
countries(12). Additionally, and to our knowledge, no articles reporting E. coli 
colonization prevalence in pregnant women in Mozambique have been 
published and only one multicenter study conducted in South Africa, Kenya and 
Rwanda have determined simultaneously the vaginal GBS and E. coli carriage 
rates in SSA(29, 30). Such data, however, appear necessary for a better and 
more evidence-based design of preventive strategies, based on the resources 
and infrastructures available. 
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This study aimed to determine the prevalence of pregnant women colonized by 
GBS and E. coli attending a semi-rural Mozambican hospital, analyze risk 
factors associated to higher risk of carriage by these pathogens and 
characterize the isolates in terms of antimicrobial resistance and serotype 
distribution. As secondary objectives, we determined the neonatal outcomes 
and assessed the feasibility and acceptability of collecting vaginal and vagino-
rectal samples among pregnant women, with the idea of generating locally-
relevant data useful to guide national preventive strategies and policies to 
reduce transmission and the toll of such potentially life-threatening infections in 
the newborn.  
 
METHODS 
Study site 
The study was conducted in Manhiça, a semi-rural site in Southern 
Mozambique. The Manhiça Health Research Center (CISM) runs a 
Demographic Surveillance System (DSS) in the area and a morbidity 
surveillance system (MSS) at the Manhiça District Hospital (MDH), across the 
street. A detailed description of MDH, CISM and the study area can be found 
elsewhere(31). MDH is the referral hospital for the Manhiça district, covering a 
population of circa 183,000 inhabitants.  The MDH includes adult and paediatric 
wards, together with a maternity, where between 3500-4000 deliveries take 
place annually. Institutional delivery rates are around 85-90% in the study area. 
MDH also includes an outpatient department and an antenatal care (ANC) clinic 
where pregnant women are routinely followed. As part of the National policy, all 
pregnant women are invited to attend antenatal consultations during their 
pregnancy, where HIV testing and other screening of infections and conditions 
are routinely offered, in addition to intermittent preventive treatment during 
pregnancy (IPTp) for malaria prevention, a disease highly endemic in the area. 
Manhiça district has one of the highest prevalence rates of HIV in the world, 
with HIV prevalence during pregnancy having been estimated at around 29% 
during antenatal consultations(32). No strategy to prevent neonatal sepsis is 
currently implemented in Mozambique. The hospital has recently introduced 
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WHO-recommended Option B+ for the prevention of mother-to-child HIV 
transmission, which is offered to mothers free of charge. 
 
Study design and population. 
This observational prospective study was conducted at the ANC and delivery 
wards of MDH, between June 15 2014 and January 15 2015, running 
continuously during working hours (8:00–16:00) and working days. We recruited 
pregnant women at two different time-points during their pregnancy. One group 
during routine antenatal care with a minimum estimated gestational age ≥34 
weeks, as measured by fundal height >=32cm, 2 cm above the midpoint 
between umbilicus and xiphoyd process. A second group of women was 
recruited upon delivery (regardless of gestational age) if they were not recruited 
at ANC clinics, in order to understand real life risk for vertical transmission rate 
of GBS or E. coli to their offspring with no interference of antibiotic treatments. 
Participants were eligible for inclusion if they lived in the study area, were in 
good physical and mental health, able and willing to participate in the study and 
to provide informed consent. All women fulfilling inclusion criteria were eligible 
to participate in the study, and in order to obtain a more representative sample 
of the study population, the first two women seen every day were approached 
for recruitment. 
 
Definitions 
GBS colonization was considered in the event of a positive vaginal or vagino-
rectal culture for GBS. E. coli colonization was considered when the positive 
vaginal culture grew E. coli. E. coli urinary tract infection was diagnosed when 
E. coli grew (>105 colony-forming units/mL) in the urine samples of pregnant 
women. Abortion was defined as pregnancy termination prior to 20 weeks' 
gestation or a foetus born weighting less than 500 g(33). A preterm baby was 
defined as that with a gestational age at birth <37 weeks and stillbirth as 
intrauterine deaths occurring after 28 weeks of gestational age. Low-birth 
weight was defined as weight at birth <2,500 grams.  
Study procedures 
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Sampling procedures 
Microbiological swab samples were obtained from each participant (ANC or 
upon admission in labour at the delivery wards, but always prior to delivery) 
without the use of antiseptic solution or a speculum. A sample from the lower 
third of the vagina and a fresh urine sample were taken for E. coli 
determination. For GBS determination, samples included a lower vaginal swab 
(vaginal sample), and a single swab for the vagino-rectal sample, consisting on 
a sample of the vagina first and then the rectum obtained performing a brief 
rotation of the swab through the outer sphincter. Both kinds of swabs were 
collected in all women in order to compare the prevalence of GBS colonization 
detected by the two samples. Swabs were immediately placed in Amies 
transport medium and sent to the laboratory within 24 hours. The vaginal and 
vagino-rectal samples for GBS determination were inoculated directly onto 
Granada medium (Group B Streptococcus Differential Agar, Becton Dickinson, 
Erembodegem, Belgium) incubated anaerobically at 37ºC for 24 hours. Vaginal 
samples for E. coli determination were spread onto MacConkey agar and urine 
samples were inoculated onto agar Cysteine lactose electrolyte deficient 
(CLED) and MacConkey agar and incubated at 37ºC overnight without C02. E. 
coli isolates were identified based on colony appearance, Gram stain, latex 
agglutination with the Pastorex Strepto kit (Bio-rad Laboratories®, Marnes-la-
Coquette, France) and standard biochemical tests for E. coli determination. 
Both, GBS and E. coli isolates were confirmed by MALDI-TOF. Resistance 
profiles were determined via Kirby-Bauer disk diffusion method following the 
Clinical & Laboratory Standards Institute (CSLI) guidelines.  
Determination of the GBS capsular type or serotype implied the utilization of a 
multiplex-PCR using a set of primers described previously(34). DNA of each 
isolate was obtained using the High Pure PCR Template Preparation kit 
(Roche, Spain). Briefly, this procedure consisted in performing three PCR 
reactions using specific primers for 10 different serotypes. Reaction 1 detects 
[Ia, Ib, II, III and IV], reaction 2 [V, VI, VII, VIII and IX] and reaction 3 is the 
amplification control. PCR conditions involved an initial step of 95ºC for 3 min, 
followed by 30 cycles of 95º C for 1 min, 57º C for 1 min and 72º C for 2 min, 
and a final step of 72º C for 10 min The PCR products were visualized by 
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electrophoresis using 1% agarose gels. Antibody (AB) determination was 
identified in blood samples of mothers recruited at delivery. They were 
performed by ELISA using whole bacteria as antigens. This procedure is a 
modification based on the protocol proposed by Baker et al (33), using an 
optical density to 450 nm with a correction at 620 nm. The cut-off value for 
positivity was chosen to be ≥ 1 OD units, in order to be more strict than the one 
proposed by Baker (>0.125). 
Maternal HIV infection status was determined and recorded if not previously 
known. Other screening tests routinely performed at ANC, such as syphilis or 
hemoglobin determination were also performed and recorded.  
 
Communication of results to mothers and case management 
Clinical assessment and management of patients was done following 
international guidelines for countries with no clear screen-and-treat national 
rules, both at the ANC and at the maternity. For those women identified as 
carriers of GBS in vagino-rectal swabs collected at the ANC, a field worker 
delivered to the mother at home a study card detailing the microbiological 
findings, together with indications of what to do during delivery, so that 
intrapartum antibiotics could be administered to the mother, following the CDC 
guidelines(35). Urinary tract infections secondary to E. coli were also reported 
and treated according to national guidelines for pregnant women. All recruited 
women were encouraged to deliver at hospital and clinical staff was trained to 
identify them. Any child born to a recruited mother and found to be sick at 
delivery was assessed by a study clinician, and routine screening for bacterial 
surveillance (including a blood culture and a lumbar puncture to obtain 
cerebrospinal fluid (CSF)) performed and clinical management organized 
according to MDH guidelines. 
Although the aim of this study was not to assess the efficacy of IAP (already 
known), due to ethical considerations, IAP was started in GBS infected women 
upon labour initiation, according to CDC guidelines(35). In cases where IAP 
could not be adequately performed, we followed Spanish recommendations and 
prophylactic antibiotic treatment (50,000 IU of intramuscular penicillin as a 
single dose for a newborn weighting >2000 grams, or 25.000 IU if weight <2000 
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 9 
grams) was administered within the first hour after birth to the newborns of 
mothers with confirmed GBS colonization(36). Such children were observed at 
hospital for a minimum of 24h. For women recruited at delivery, culture results 
were not available until at least 24-48h after recruitment. In such cases (and 
also in cases of women with pending GBS result recruited prior to delivery) we 
kept the newborns under observation for a minimum of 24 hours after delivery, 
and provided clear recommendations to mothers regarding the need for a follow 
up visit should the newborn become sick in the first weeks of life. Babies born to 
study participant mothers were followed-up during the first three months after 
birth.  
 
Assessment of the acceptability of vaginal and vagino-rectal sampling 
The study included a simple socio-behavioural component to evaluate the 
acceptability of collecting samples (vaginal and vagino-rectal swabs) during 
pregnancy. "Non-participant observations" were conducted, whereby a member 
of the study team observed the procedures being conducted (excluding genital 
examinations), and complemented by semi-structured interviews to a small 
sample of pregnant women not participating in the study but 
contemporaneously attending the ANC. Finally, semi-structured interviews were 
conducted among some participants who had accepted to provide vaginal and 
rectal samples. Questions, themes and probes arising from the non-participant 
observation, other than stated in the interview guide, were included in the semi-
structured interviews. 
 
Statistical analysis 
All data were prospectively collected using standardized questionnaires, which 
were double entered in specific study databases, created using Openclinica© 
software. Discrepancies were solved after comparison with the original source 
documents by a senior data clerk, and in close collaboration with the study 
clinicians. Statistical analyses were performed using StataCorp. 2015. Stata 
Statistical Software: Release 14 (College Station, TX: StataCorp LP). Study 
variables were counted and summarized in frequency tables. Qualitative 
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variables were compared using a Chi-squared test or Fisher’s exact test. 
Continuous variables were described as mean (standard deviation, SD) or 
median values (interquartile range, IQR) and were compared using the t test for 
normal distributions or the Mann Whitney test for skewed data. Logistic 
regression univariate and multivariate analyses were performed to identify risk 
factors for GBS or E. coli colonization, separately. Variables that were found to 
be significantly associated with GBS or E. coli in the univariate analysis together 
with those related at a significance level of p<0.10 were entered into a 
multivariate model. Age and gestational age at recruitment were also included 
in the multivariate analysis based on previous studies(9, 15-17). A separate 
univariate and multivariate analysis of risk factor associated to GBS or E. coli 
colonization among HIV pregnant women was also performed. 
Ethical considerations 
This protocol and all supporting documentation (Informed consent documents, 
Study questionnaires) were approved by the local bioethics committee of CISM 
(Comité Institucional de Bioética para Saúde do CISM (CIBS-CISM)), and by 
the National Bioethics Committee of Maputo (CNBS) in Mozambique; and by 
the Ethics Committee of the Hospital Clínic in Barcelona, Spain. Written 
information and consent forms in the local language were provided to the 
women. After the interview, participants were asked to express their willingness 
to participate in the study by signing (or thumb-printing in case they were 
illiterate) the consent form. Participation in this study was voluntary, and study-
related procedures did not interfere with the pregnant women’s or children’s 
standard clinical care. 
 
RESULTS 
Between June 15 2014 and January 15 2015, 320 pregnant women were 
recruited at MDH (Study profile in figure 1). Table 1 summarizes the socio-
demographic and clinical characteristics of participants. Median age of recruited 
women was 24 years (Interquartile range, IQR 20-31), with no significant 
differences according to recruitment place. No major differences could be found 
in relation with recruitment site, with the exception of a higher frequency of 
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higher education among women recruited upon delivery compared with those 
recruited at ANC (7.0% vs. 26.7%, p<0.001). More than one third of women 
(117/320, 36.6%) were HIV positive.  
Prevalence of GBS and E. coli colonization among pregnant women 
More than a fifth (68/320; 21.3%) of all recruited women were colonized by 
GBS, detected in both samples in 33 women, in 15 in the vaginal one only, and 
in 20 in the vagino-rectal one only. A non-statistically significant higher 
proportion of GBS were isolated from the vagino-rectal sample (16.6%) as 
compared to the vagina (15.0%, p=0.81). Prevalence of GBS colonization was 
borderline significantly higher among women recruited upon delivery compared 
to those recruited at ANC (32/120 (26.7%) vs. 36/200 (18.0%), p=0.07).  Fifty-
two women had E. coli vaginal colonization (16.3%), being significantly more 
common among women recruited at delivery (22.5% vs. 12.5%, p=0.019) and 
10/320 (3.1%) had a positive E. coli urine culture. Among HIV positive pregnant 
women recruited, GBS colonization was found in 26/117 (22.2%). E. coli vaginal 
colonization was determined in 18/117 (15.4%) HIV-positive women. 
Anti-group B streptococcus antibodies 
Antibodies against GBS were detected in 83/120 (69.1%) women recruited at 
delivery. Of them, 23/32 (71.9%) were among GBS colonized mothers and 
60/88 (68.2%) among non-colonized women (figure 2). Among HIV positive 
participants, AB anti-GBS were detected in 25/38 (65.8%) of those tested. Forty 
women had AB against more than one GBS serotype, being the most frequent 
AB against serotype Ia (24/120, 20%), against serotype Ib (76/120, 63.3%) and 
against serotype V (27/120, 22.5%). Correlating presence of antibodies to the 
homotypic GBS serotype, 2/4 (50%) women colonized by serotype Ia had AB 
against it, 6/6 (100%) for serotype Ib, 0/3 (0%) for serotype III and 7/14 (50%) of 
those carriers of Ib serotype had AB against their homotypic serotype. 
Risk factors associated to GBS and E. coli carriage 
Table 2 presents the univariate analyses of associations of the different socio-
demographics, clinical and laboratory variables with vaginal GBS and E. coli 
carriage. In the final multivariate GBS model (Table 3), no risk factors were 
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significantly associated with GBS carriage. Similarly, no risk factors appeared to 
be independently associated with maternal vaginal E. coli carriage (table 4). 
The univariate and multivariate analyses performed to identify risk factors of 
GBS or E. coli colonization but restricted to HIV-infected women showed no 
differences compared to those including all women (data not shown). 
Antimicrobial susceptibility and serotyping 
One hundred and one specimens were found to be positive for GBS (48 vaginal 
and 53 vagino-rectal). All GBS isolates were fully sensitive to penicillin, 
ampicillin and ceftriaxone. Thirty-four (32.7%) isolates were resistant to 
erythromycin and 20 (19.2%) isolates to clindamycin. Seven isolates showed 
erythromycin-induced resistance to clindamycin. All the E. coli isolates were 
screened for susceptibility to 18 antimicrobial agents. Susceptibility to all 
antimicrobial agents tested was seen in 14 isolates (22.6%). E. coli was 
resistant to ampicillin in 21 (38.9%) cases, ceftriaxone in 2 (3.2%) cases, 
amoxicillin/clavulanate acid in 12 cases (19.4%), ciprofloxacin in 4 cases (6.5%) 
and co-trimoxazole in 38 cases (61.3%). Figure 3 summarizes the distribution of 
antimicrobial resistance (classifying isolates showing intermediate levels of 
susceptibility as resistant). Details of the resistance profiles of GBS and E. coli 
isolates are shown in Supplementary material table S1. 
The serotype distribution of the GBS isolates is presented in Fig 4 and Fig S1 in 
the Supplementary material. The most prevalent serotypes were V (32.4%), Ia 
(14.7%), III and Ib (10.3% and 8.8%, respectively). Sixteen isolates (23.5%) 
were non-typeable. Twenty-six women had the same serotype detected both in 
the vaginal and vagino-rectal swabs, while in seven cases infections were 
serotype-discordant.  
 Neonatal outcomes 
Three hundred and twenty neonatal outcomes from 316 pregnant women were 
recorded (98.8%). The delivery outcomes of four women in the ANC group were 
not registered at MDH. Neonatal outcomes included four pair of twins, 290 term 
babies, 25 preterm and 5 cases of stillbirths. Figure 1 illustrates neonatal 
outcomes and follow-up in detail. Characteristics of neonates born of mothers 
participating in the study may be found in table 1 and 2. Thirty-two neonates 
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born of 36 (88.9%) GBS carriers recruited at ANC were born at MDH, and 4 
outside of the health system. Due to lack of qualified clinical staff, work 
saturation and advanced stage of labor, IAP strategy as recommended by 
CDC(35) was  feasible only in two known GBS carriers at time of delivery, we 
administered a single dose of penicillin to 22 neonates in the first hour after 
birth. Two hundred and sixty-two infants (81.9%) were followed-up until 90 days 
of age and 8/262 (3.1%) were admitted in the hospital during this period. Seven 
infants died among those followed-up until 3 months after birth (2.7%), being 
five of them HIV-exposed (one clinical sepsis, one perinatal asphyxia and 3 
unknown causes). A significantly higher risk for death among those neonates 
born of mothers recruited at ANC compared to those recruited at delivery (3.6% 
vs. 1.7%, p<0.001) was found.  
 
Acceptability of vaginal and vagino-rectal sampling 
Fifteen study participant women and five non-study pregnant women were 
recruited for the social component. Acceptability of collecting vaginal and 
vagino-rectal samples was 100%. Facilitators for acceptance included: a) 
Willingness to know whether they had a reproductive tract infection; b) Being 
interested in understanding the objectives of collecting vaginal and vagino-rectal 
samples; and c) Willingness to be treated and accompanied to the hospital in 
case of reproductive tract infection and avoiding transmitting them to their 
offsprings. Only a few women felt uncomfortable with sample collection, 
referring to feeling of burning and/or pain. Although all participants of the social 
component accepted sample collection, possible barriers for acceptance of 
future vagino-rectal sample collection were explored and these included: a) fear 
in relation to the first time being submitted to this procedure; b) worries 
regarding being seen at the hospital (stigma); c) lack of privacy at the ANC at 
time of sample collection. 
 
DISCUSSION 
To our knowledge, this is the first study presenting data on GBS maternal 
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colonization, antibodies against GBS and characterization of isolates in a rural 
area of Mozambique and the first time concomitantly examining E. coli 
colonization in pregnant women in the country. Maternal rate of GBS 
colonization found in this study, 21.3%, was as high as previous work in other 
countries in Sub-Saharan Africa reported(12). However, two previous studies 
performed in the capital of Mozambique, Maputo, reported an extremely low 
prevalence of GBS colonization among pregnant women of 1% in 1995(27) and 
1.8% in 2008(25). Smaller sample sizes, different study population, and very 
likely laboratory and microbiology procedures utilized for GBS detection, may all 
contribute to explain the significant increase in terms of overall prevalence 
found in our study. Our findings are in close agreement with a systematic review 
on GBS disease in sub-Saharan Africa(12), which included 18 studies reporting 
data on maternal GBS colonization, finding an average GBS carriage of 21.8% 
(95% CI: 18.3 - 25.5) among pregnant women across the region. These results 
are also similar to general prevalence data from other regions, including the 
United States(9) and Europe(13), or from other neighboring countries in Sub-
Saharan Africa such as South Africa (with similar prevalence of HIV(20, 37, 38), 
Zimbabwe(15) or Malawi(39), supporting the credibility of these data. The yield 
of vagino-rectal sampling was better for GBS colonization than using only 
vaginal samples as previously reported(40, 41) and recommended(35).   
No risk factors independently associated with higher prevalence of GBS 
colonization were found in this study. We adjusted the multivariate analysis by 
gestational age as previous studies examining the influence of advancing 
gestation on GBS colonization have observed that colonization rates appear to 
change overtime during pregnancy(15, 42, 43). However, no associations 
between gestational age and colonization risk by GBS were found. Colonization 
prevalence was similar among age groups, in contrast to what has been 
described by some studies(16, 17, 44) but in concordance to a recent 
multicenter study performed in African settings(37), reinforcing the idea that 
colonization rates are quite stable across a wide variety of African settings. We 
did not find higher education to be a risk factor for GBS colonization as other 
studies have reported(18), a finding possibly influenced by the homogeneity of 
lower education backgrounds in our setting. Importantly, this study further 
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contributes to expose the fact that current understanding on maternal risk 
factors for colonization is incomplete. 
No increased risk of GBS colonization among HIV-infected women was found in 
this study, a finding supported by other studies in USA and Zimbabwe(15, 19). 
However, a South African study reported that maternal GBS carriage was lower 
in HIV-positive women and among those with lower CD4 counts in Malawi(20, 
39). This fact could be related to the fact that GBS carriage is inversely 
associated with the use of prophylactic co-trimoxazole among HIV-infected 
women. Information about co-trimoxazole use in this study was not recorded but 
due to high prevalence of HIV in our cohort it is likely that a high proportion of 
participants were routinely taking co-trimoxazole. Although HIV appears not to 
be a risk factor for maternal colonization during pregnancy, a recent South 
African study found that incidence of GBS neonatal disease may be up to 64% 
higher among HIV-exposed infants compared with non-HIV exposed ones(12). 
As of today, no data are available regarding incidence of neonatal GBS invasive 
disease and HIV co-infection in Mozambique. However, studies conducted in 
South Africa(20, 45), with a similar HIV prevalence to the one reported in 
southern Mozambique(32), found an incidence of GBS invasive disease among 
infants higher than that reported in other resource-constrained settings(44, 46). 
Hence, it would appear reasonable to expect a high incidence of GBS invasive 
disease in this particularly HIV-struck study area. However, a low incidence of 
GBS invasive cases in neonates born to GBS infected women was found in this 
study. Reasons for this low incidence could be the high prevalence of 
antibodies against GBS found in the studied cohort (69.2%). Maternal antibody 
levels have been associated with protection against invasive GBS disease in 
high(47) and lower-middle income settings(48) and it has been documented that 
GBS placental transfer appears not to be affected by HIV infection(49). It is 
difficult to correlate our GBS AB results with what is known regarding GBS 
maternal colonization and infant disease. The highest proportion of women with 
anti-GBS AB was against serotype Ib, Ia and V, consistent with predominant 
serotypes among carriers in our cohort. Although we did not examine antibody 
correlation between mothers and newborns, the higher prevalence of antibodies 
in our cohort could also potentially explain this low incidence of GBS invasive 
disease among our neonate cohort. In addition, prevalence of carriers of 
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serotype III in this population, the known serotype causing more infant invasive 
disease(50), was lower than reported in other African studies(12), which would 
be also consistent with a lower incidence among infants. Another reason could 
be the attempt to implement IAP strategy to those colonized GBS mothers 
delivering at MDH. None of the neonates who received a single dose of 
penicillin after birth developed symptoms of sepsis. Understanding that this 
strategy is not generally recommended on account of the risks of enhancing 
antimicrobial resistance, and in spite of the small sample, it could be argued 
that for settings were access to health is problematic, but where GBS maternal 
carriage can be confirmed, such a strategy could prove effective in decreasing 
neonatal early morbidity by blocking the infection’s transmissibility at a moment 
where the baby is still under the surveillance of the health system. The only 
GBS case in our study was a newborn developing symptoms in the first 24 
hours, born to a mother recruited at delivery with negative GBS screening. This 
mother was HIV positive and was taking co-trimoxazole as prophylaxis of 
opportunistic infections, suggesting an intrauterine infection with a subsequent 
negativization.  
 
On the other hand, the prevalence of E. coli found in this study was lower than 
reported from other authors in different African settings(20, 37) but comparable 
with the prevalence reported by Karou in Togo(51). No risk factors were found 
to be independently associated with a higher risk of E. coli vaginal carriage 
among pregnant women. Some studies have reported specific risks factors for 
E. coli colonization, including sexual practices such as anal intercourse during 
pregnancy(52) or being a sexual worker(37). Such factors were however not 
explored in our study.  
Importantly, GBS continues to be susceptible to penicillin, ampicillin, and 
ceftriaxone in this setting. Previous studies in Ethiopia(53, 54) and South 
Africa(18, 51) also reported full susceptibility of GBS strains to penicillin. Rarer 
cases of decreased susceptibility to penicillin have been reported in Japan and 
the United States(55). A study in Zimbabwe found almost 100 % of isolates 
sensitive to penicillin, with 2% showing intermediate susceptibility to penicillin.  
Resistance to erythromycin resistance among invasive GBS isolates in Europe 
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ranges from 3.8% to 21.2%(13) and from 7% to 25% in the USA and 
Canada(24). Higher levels of resistance to erythromycin (~33%) were found in 
this study which could be related to mass drug administration (MDA) of 
azithromycin for trachoma control in sub-Saharan Africa since development of 
macrolide-resistant pathogens after more than one round of mass treatment has 
already reported(56, 57). Erythromycin resistance is frequently associated with 
clindamycin resistance(24). The emergence of non-susceptible GBS strains has 
important public health implications. GBS is still susceptible to penicillin and 
ampicillin which are the antibiotics of choice. Erythromycin and clindamycin are 
the drugs of choice for penicillin-hypersensitive patients and resistance to these 
antibiotics is emerging.  
As other studies have reported(12), serotypes Ia, Ib, II, III and V were 
predominant. However, the most frequent serotype (V) found in this study 
differs from those found in the majority of studies conducted in other countries, 
revealing the need to identify prevalent serotypes in each region, as a 
prerequisite of establishing the potential coverage, impact and implementation 
requirements of future anti GBS vaccination strategies.  
Characterization of E. coli isolates from this study has been described by Saez 
et al(58). E. coli isolates showed significant resistance to co-trimoxazole, as a 
previous study on diarrhoeagenic E. coli(59) conducted in Manhiça already 
described. Reasons for such high SXT resistance levels may include its 
extensive use as treatment of community-acquired infections, or as prophylaxis 
of HIV-related opportunistic infections(60).  
This study has several limitations. Only women attending the MDH (and no 
other maternities) were included, and recruitment was not conducted after 
working hours, these being potential sources of selection bias and limiting the 
generalization of our results to the entire district. The first two women fulfilling 
inclusion criteria every day were invited to participate in the study, leading to 
only 200 women being recruited at ANC, and 120 additional ones upon delivery, 
an estimated 10% of all deliveries per year attended at MDH. Pregnant women 
are less likely to attend ANC at the end of their pregnancies, and some women 
who attend antenatal care in other maternities do actually choose MDH to 
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deliver. Altogether this justifies our sampling strategy, but it is important to 
highlight that this convenience sample may not be truly representative of the 
entire pregnancy cohort in the area. We did not collect information about 
population not sampled and we were unable to compare it with our population in 
order to assess such potential selection bias. However, the maternity at MDH is 
the biggest one in the study area and women seen there come from different 
places of the district and a sample of women attended at delivery was also 
recruited, minimizing bias. Other studies have reported association of other 
sexually transmitted infections such as gonorrhea or bacterial vaginosis(37) or 
socio-economic status(44) with GBS colonization in pregnant women, but we 
did not measure these variables. However, an attempt was made to explore the 
majority of potential risk factors described by other authors. Finally, and albeit 
this not being an objective of the study, it was impossible to assess the risk of 
GBS and E. coli transmission in this cohort, due the lack of denominator.  
 
Conclusion 
This study shows GBS and E. coli carriage among near term pregnant women 
is high in southern Mozambique. HIV infection was not a risk factor for GBS or 
E. coli colonization. Presence of anti-GBS antibodies, administration of single 
dose of penicillin to neonates born to colonized mothers or use of prophylactic 
co-trimoxazole among HIV-infected pregnant women could be reasons 
explaining the low incidence of GBS invasive disease among our cohort of 
newborns.  
Screening mothers near term and providing appropriate antimicrobial 
prophylaxis could prevent potential adverse neonatal outcomes. Unfortunately, 
the fragility of the health system in LIC hinders the applicability of such 
approaches, and calls for innovative ideas to tackle these vertically transmitted 
infections. Serotype V was the most prevalent in our community and four 
serotypes cause the majority of cases of GBS colonization. The development 
and implementation of a conjugate vaccine incorporating the most commonly 
found serotypes globally, could enhance the transfer of maternal antibodies to 
the baby and protect their health in those critical first moments for survival. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 19 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 20 
REFERENCES 
1. United Nations. Levels & Trends Child Mortality. Estimates Developed by the UN Inter-
agency Group for Child Mortality Estimation. Report 2017. Available at: 
http://www.childmortality.org/index.php?r=site/index ; (accessed Nov 11, 2017). . In: Fund 
UNCs, ed. New York2017. 
2. Liu L, Oza S, Hogan D, et al. Global, regional, and national causes of under-5 mortality in 
2000-15: an updated systematic analysis with implications for the Sustainable Development 
Goals. Lancet. 2016;388:3027-3035. 
3. UNICEF. Levels &amp; Trends in child mortality [Internet]. 2015 [cited 2017 Apr 26]. 
Available from: https://data.unicef.org/wp-content/uploads/2015/12/IGME-report-2015-child-
mortality-final_236.pdf 2015. 
4. Neto MT. Group B streptococcal disease in Portuguese infants younger than 90 days. Arch 
Dis Child Fetal Neonatal Ed. 2008;93:F90-93. 
5. Stoll BJ, Hansen N, Fanaroff AA, et al. Changes in pathogens causing early-onset sepsis in 
very-low-birth-weight infants. N Engl J Med. 2002;347:240-247. 
6. Van Dyke MK, Phares CR, Lynfield R, et al. Evaluation of universal antenatal screening for 
group B streptococcus. N Engl J Med. 2009;360:2626-2636. 
7. Guilbert J, Levy C, Cohen R, Delacourt C, Renolleau S, Flamant C. Late and ultra late onset 
Streptococcus B meningitis: clinical and bacteriological data over 6 years in France. Acta 
Paediatr. 2009;99:47-51. 
8. Acosta CD, Kurinczuk JJ, Lucas DN, et al. Severe maternal sepsis in the UK, 2011-2012: a 
national case-control study. PLoS Med. 2014;11:e1001672. 
9. Krohn MA, Thwin SS, Rabe LK, Brown Z, Hillier SL. Vaginal colonization by Escherichia coli as 
a risk factor for very low birth weight delivery and other perinatal complications. J Infect Dis. 
1997;175:606-610. 
10. Beck S, Wojdyla D, Say L, et al. The worldwide incidence of preterm birth: a systematic 
review of maternal mortality and morbidity. Bull World Health Organ. 2010;88:31-38. 
11. Khan KS, Wojdyla D, Say L, Gulmezoglu AM, Van Look PF. WHO analysis of causes of 
maternal death: a systematic review. Lancet. 2006;367:1066-1074. 
12. Sinha A, Russell LB, Tomczyk S, et al. Disease Burden of Group B Streptococcus Among 
Infants in Sub-Saharan Africa: A Systematic Literature Review and Meta-analysis. Pediatr Infect 
Dis J. 2016;35:933-942. 
13. Barcaite E, Bartusevicius A, Tameliene R, Kliucinskas M, Maleckiene L, Nadisauskiene R. 
Prevalence of maternal group B streptococcal colonisation in European countries. Acta Obstet 
Gynecol Scand. 2008;87:260-271. 
14. Kwatra G, Adrian PV, Shiri T, Buchmann EJ, Cutland CL, Madhi SA. Serotype-specific 
acquisition and loss of group B streptococcus recto-vaginal colonization in late pregnancy. PLoS 
One. 2014;9:e98778. 
15. Mavenyengwa RT, Afset JE, Schei B, et al. Group B Streptococcus colonization during 
pregnancy and maternal-fetal transmission in Zimbabwe. Acta Obstet Gynecol Scand. 
2010;89:250-255. 
16. Anthony BF, Okada DM, Hobel CJ. Epidemiology of group B Streptococcus: longitudinal 
observations during pregnancy. J Infect Dis. 1978;137:524-530. 
17. Regan JA, Klebanoff MA, Nugent RP. The epidemiology of group B streptococcal 
colonization in pregnancy. Vaginal Infections and Prematurity Study Group. Obstet Gynecol. 
1991;77:604-610. 
18. Stapleton RD, Kahn JM, Evans LE, Critchlow CW, Gardella CM. Risk factors for group B 
streptococcal genitourinary tract colonization in pregnant women. Obstet Gynecol. 
2005;106:1246-1252. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 21 
19. Shah M, Aziz N, Leva N, Cohan D. Group B Streptococcus colonization by HIV status in 
pregnant women: prevalence and risk factors. J Womens Health (Larchmt). 2011;20:1737-
1741. 
20. Cutland CL, Schrag SJ, Zell ER, et al. Maternal HIV infection and vertical transmission of 
pathogenic bacteria. Pediatrics. 2012;130:e581-590. 
21. Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of 
intrapartum antibiotic prophylaxis. N Engl J Med. 2000;342:15-20. 
22. Prevention of perinatal group B streptococcal disease: a public health perspective. Centers 
for Disease Control and Prevention. MMWR Recomm Rep. 1996;45:1-24. 
23. Melin P, Schmitz M, De Mol P, Foidart JM, Rigo J. [Group B streptococcus, primary cause of 
life-threatening infections in infants. Epidemiology and prevention strategy]. Rev Med Liege. 
1999;54:460-467. 
24. Schrag S, Gorwitz R, Fultz-Butts K, Schuchat A. Prevention of perinatal group B 
streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep. 2002;51:1-22. 
25. de Steenwinkel FD, Tak HV, Muller AE, Nouwen JL, Oostvogel PM, Mocumbi SM. Low 
carriage rate of group B streptococcus in pregnant women in Maputo, Mozambique. Trop Med 
Int Health. 2008;13:427-429. 
26. Sigauque B, Roca A, Mandomando I, et al. Community-acquired bacteremia among children 
admitted to a rural hospital in Mozambique. Pediatr Infect Dis J. 2009;28:108-113. 
27. Osman NB, Folgosa E, Bergstrom S. An incident case-referent study of threatening preterm 
birth and genital infection. J Trop Pediatr. 1995;41:267-272. 
28. Nhantumbo AA, Cantarelli VV, Caireao J, et al. Frequency of Pathogenic Paediatric Bacterial 
Meningitis in Mozambique: The Critical Role of Multiplex Real-Time Polymerase Chain Reaction 
to Estimate the Burden of Disease. PLoS One. 2015;10:e0138249. 
29. Capan M, Mombo-Ngoma G, Akerey-Diop D, et al. Epidemiology and management of group 
B streptococcal colonization during pregnancy in Africa. Wien Klin Wochenschr. 2012;124 Suppl 
3:14-16. 
30. Stoll BJ, Schuchat A. Maternal carriage of group B streptococci in developing countries. 
Pediatr Infect Dis J. 1998;17:499-503. 
31. Sacoor C, Nhacolo A, Nhalungo D, et al. Profile: Manhica Health Research Centre (Manhica 
HDSS). Int J Epidemiol. 2013;42:1309-1318. 
32. Gonzalez R, Munguambe K, Aponte J, et al. High HIV prevalence in a southern semi-rural 
area of Mozambique: a community-based survey. HIV Med. 2012;13:581-588. 
33. Schorge John O SJI, Halvorson Lisa M, Hoffman Barbara L, Bradshaw Karen D, Cunningham 
F Gary.  . 6. First-Trimester Abortion: McGraw-Hill Medical; 2008. 
34. Poyart C, Tazi A, Reglier-Poupet H, et al. Multiplex PCR assay for rapid and accurate 
capsular typing of group B streptococci. J Clin Microbiol. 2007;45:1985-1988. 
35. Verani Jennifer R ML, Schrag Stephanie J. . Prevention of perinatal group B streptococcal 
disease--revised guidelines from CDC, 2010. MMWR Recommendations and reports : Morbidity 
and mortality weekly report Recommendations and reports. 2010;59:1-36. 
36. Alos Cortes JI, Andreu Domingo A, Arribas Mir L, et al. [Prevention of Neonatal Group B 
Sreptococcal Infection. Spanish Recommendations. Update 2012. 
SEIMC/SEGO/SEN/SEQ/SEMFYC Consensus Document]. Enferm Infecc Microbiol Clin. 
2013;31:159-172. 
37. Cools P, Jespers V, Hardy L, et al. A Multi-Country Cross-Sectional Study of Vaginal Carriage 
of Group B Streptococci (GBS) and Escherichia coli in Resource-Poor Settings: Prevalences and 
Risk Factors. PLoS One. 2016;11:e0148052. 
38. Cutland CL, Madhi SA, Zell ER, et al. Chlorhexidine maternal-vaginal and neonate body 
wipes in sepsis and vertical transmission of pathogenic bacteria in South Africa: a randomised, 
controlled trial. Lancet. 2009;374:1909-1916. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 22 
39. Gray KJ, Kafulafula G, Matemba M, Kamdolozi M, Membe G, French N. Group B 
Streptococcus and HIV infection in pregnant women, Malawi, 2008-2010. Emerg Infect Dis. 
2011;17:1932-1935. 
40. Gupta C, Briski LE. Comparison of two culture media and three sampling techniques for 
sensitive and rapid screening of vaginal colonization by group B streptococcus in pregnant 
women. J Clin Microbiol. 2004;42:3975-3977. 
41. Wang X, Ma LK, Song YN, Liu JT, Xu YC, Yi J. [Rapid Group B streptococcus screening 
methods in late pregnancy and the maternal-neonatal outcomes]. Zhonghua Yi Xue Za Zhi. 
2016;96:1188-1191. 
42. Baker CJ, Barrett FF, Yow MD. The influence of advancing gestation on group B 
streptococcal colonization in pregnant women. Am J Obstet Gynecol. 1975;122:820-823. 
43. Hansen SM, Uldbjerg N, Kilian M, Sorensen UB. Dynamics of Streptococcus agalactiae 
colonization in women during and after pregnancy and in their infants. J Clin Microbiol. 
2004;42:83-89. 
44. Seale AC, Koech AC, Sheppard AE, et al. Maternal colonization with Streptococcus 
agalactiae and associated stillbirth and neonatal disease in coastal Kenya. Nature microbiology. 
2016;1:16067. 
45. Dangor Z, Lala SG, Cutland CL, et al. Burden of invasive group B Streptococcus disease and 
early neurological sequelae in South African infants. PLoS ONE. 2015;10 (4) (no pagination). 
46. Gray KJ, Bennett SL, French N, Phiri AJ, Graham SM. Invasive group B streptococcal 
infection in infants, Malawi. Emerg Infect Dis. 2007;13:223-229. 
47. Dangor Z, Kwatra G, Izu A, Lala SG, Madhi SA. Review on the association of Group B 
Streptococcus capsular antibody and protection against invasive disease in infants. Expert Rev 
Vaccines. 2015;14:135-149. 
48. Dangor Z, Kwatra G, Izu A, et al. Correlates of protection of serotype-specific capsular 
antibody and invasive Group B Streptococcus disease in South African infants. Vaccine. 
2015;33:6793-6799. 
49. Le Doare K, Taylor S, Allen L, et al. Placental transfer of anti-group B Streptococcus 
immunoglobulin G antibody subclasses from HIV-infected and uninfected women to their 
uninfected infants. AIDS. 2016;30:471-475. 
50. Edmond KM, Kortsalioudaki C, Scott S, et al. Group B streptococcal disease in infants aged 
younger than 3 months: systematic review and meta-analysis. Lancet. 2012;379:547-556. 
51. Karou SD, Balaka A, Bamoke M, et al. Epidemiology and antibiotic resistance of bacterial 
meningitis in Dapaong, northern Togo. Asian Pac J Trop Med. 2012;5:848-852. 
52. Tameliene R, Barcaite E, Stoniene D, et al. Escherichia coli colonization in neonates: 
prevalence, perinatal transmission, antimicrobial susceptibility, and risk factors. Medicina 
(Kaunas). 2012;48:71-76. 
53. Alemseged G, Niguse S, Hailekiros H, Abdulkadir M, Saravanan M, Asmelash T. Isolation 
and anti-microbial susceptibility pattern of group B Streptococcus among pregnant women 
attending antenatal clinics in Ayder Referral Hospital and Mekelle Health Center, Mekelle, 
Northern Ethiopia. BMC Res Notes. 2015;8:518. 
54. Mengist A, Kannan H, Abdissa A. Prevalence and antimicrobial susceptibility pattern of 
anorectal and vaginal group B Streptococci isolates among pregnant women in Jimma, 
Ethiopia. BMC Res Notes. 2016;9:351. 
55. Dahesh S, Hensler ME, Van Sorge NM, et al. Point mutation in the group B streptococcal 
pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob Agents 
Chemother. 2008;52:2915-2918. 
56. Bojang E, Jafali J, Perreten V, et al. Short-term increase in prevalence of nasopharyngeal 
carriage of macrolide-resistant Staphylococcus aureus following mass drug administration with 
azithromycin for trachoma control. BMC Microbiol. 2017;17:75. 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 23 
57. Skalet AH, Cevallos V, Ayele B, et al. Antibiotic selection pressure and macrolide resistance 
in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial. PLoS Med. 
2010;7:e1000377. 
58. Saez-Lopez E, Cossa A, Benmessaoud R, et al. Characterization of Vaginal Escherichia coli 
Isolated from Pregnant Women in Two Different African Sites. PLoS One. 2016;11:e0158695. 
59. Mandomando IM, Macete EV, Ruiz J, et al. Etiology of diarrhea in children younger than 5 
years of age admitted in a rural hospital of southern Mozambique. Am J Trop Med Hyg. 
2007;76:522-527. 
60. Chintu C, Bhat GJ, Walker AS, et al. Co-trimoxazole as prophylaxis against opportunistic 
infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-
controlled trial. Lancet. 2004;364:1865-1871. 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 24 
LEGENDS FOR FIGURES 
Figure 1.  Study profile. 
ANC: antenatal clinics; IC: informed consent; IAP: intrapartum antibiotic 
prophylaxis. MDH: Manhiça district hospital. ˠMicrobiologically not confirmed. 
ᶤNone received any kind of prophylaxis; ʶneonate died before taking samples.ʱ 
GBS sepsis without meningitis developed in the first 24h of life. 
 
Figure 2.  Bubble plot demonstrating antibodies against GBS serotype Ia, Ib, II, 
III, IV and V in blood samples from women recruited at delivery (n=120).  
  OD: optical density to 450 nm with a correction at 620 nm. Cut-off value for 
positivity was ≥ 1 OD units. 
 
Figure 3. Distribution of antimicrobial resistance among GBS and E. coli 
isolates 
PEN, penicillin; AMP, ampicillin; CTX, ceftriaxone; ERY: erythromycin; CD, 
clindamycin; TET, tetracycline; VA, vancomycin; NAL, nalidixic acid; AMC, 
amoxicillin/clavulanic acid; CXM, cefuroxime,;  FOX, cefoxitine; CAZ, 
ceftazidime; AZT, aztreonam; TZP, piperacillin/tazobactam; ETP, ertapenem; 
IPM, imipenem; MEM, meropenem; CIP, ciprofloxacin; GEN, gentamicin; SXT, 
trimethoprim/ sulfamethoxazole; TOB, tobramycin 
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Table 1. Socio-demographic and clinical characteristics of all pregnant women recruited at 
antenatal clinics or directly upon delivery. 
NA: not applicable; ᵠHAART: highly active antiretroviral therapy; ᵟP-value was derived from Chi2 test for categorical variables 
and t-test for quantitative variables.ᶤAntibiotic usage two weeks before sample collection. Data available for 259 women. 
ᶬBased on data for 262 newborns followed-up 90 days after birth. 
 
 
  
Overall 
n=320 
 
         n (%)  
Antenatal clinics 
recruitment 
 n=200 
n (%)  
Delivery 
recruitment            
n=120 
n (%)  
p valueᵟ 
Socio-demographic characteristics      
Age in years        0.040 
< 21 112 (35.0) 61 (30.5) 51 (42.5)   
  
  
22 to 29 110 (34.4) 69 (34.5) 41 (34.2) 
≥30 98 (30.6) 70 (35.0) 28 (23.3) 
               Seconday or tertiary 
education  
46 (14.4) 14 (7.0) 32 (26.7) <0.001 
               Employment  17(5.3) 11 (5.5) 6 (5.0) 0.85 
Obstetric  History         
Age of first pregnancy  (mean±SD)   18.6 (±2.6) 18.6 (±2.9) 18.7 (±2.7) 0.67 
Gravidity  (mean±SD)  2.8 (±1.8) 2.9 (±1.7) 2.7 (±1.9) 0.43 
Previous abortion  24 (7.5) 12 (6.0) 12 (10.0) 0.19 
History of current pregnancy         
  Gestational age in weeks at 
recruitment  (mean±SD)   
37.1 (±2.0) 36.0 (±1.2) 38.9 (±1.6) <0.001 
At least 3 antenatal visits during 
the pregnancy 
165 (51.6) 95 (47.5) 70 (58.3) 0.007 
Gestational hypertension  23 (7.2) 16 (8.0) 7 (5.8) 0.51 
Vaginal itching  21 (6.6) 21 (10.5) 0 (0) <0.001 
Vaginal discharge  125 (39.1) 123 (61.5) 2 (1.7) <0.001 
Urinary symptoms  3 (0.9) 3 (1.5) 0 (0.0) 0.18 
Antibiotic usageᶤ   13 (4.0) 10 (5.0) 3 (2.5) 0.10 
  Investigations  during pregnancy         
Syphilis positive 2 (0.6) 1 (0.5) 1 (0.5) 0.70 
HIV positive 117 (36.6) 79 (39.5) 38 (31.7) 0.16 
HIV positive on HAARTᵠ 111 (94.9) 77 (97.5 ) 34 (89.5) 0.024 
Anemia (<11g/dL)ʱ 206 (64.4) 152 (76.0) 54 (45.0) 0.047 
  Neonatal Outcome          
Gestational age at birth         
Term newborn  290 (90.6) 177 (88.5) 113 (94.2)  0.09 
Pre term newborn  30 (7.8) 23 (9.5) 7 (5.0)   
Stillbirth  5 (1.6) 4 (2.0) 1 (0.8) 0.26 
Low birth weight (<2500g) 31 (9.7) 9 (4.5) 22 (18.3) <0.001 
Death after birthᶬ 7 (2.7) 5 (3.6) 2 (1.7) <0.001 
     
Table
Table 2.  Univariate analysis of socio-demographic and clinical variables among women colonized by GBS or E. 
coli 
  
GBS 
colonized   
n= 68,  
n (%) 
GBS 
uncolonized   
n=252,  
n (%) 
Crude OR 
(95%CI) 
p 
valueᵟ 
E. coli 
colonized   
n= 52,  
n (%) 
E. coli 
uncolonized   
n=268,        
n (%) 
Crude OR 
(95%CI) 
p 
valueᵟ 
Socio-demographic 
characteristics 
                
Age in years       0.70       0.70 
< 21 21 (30.9) 91 (36.1) 1.00   18 (34.6) 94 (35.1) 1.00   
22 to 29 24 (35.3) 86 (34.1) 1.21 (0.6 - 2.3) 
 
18 (34.6) 92 (34.3) 1.02 (0.5- 2.1) 
 
≥30 23 (33.8) 75 (29.8) 1.33 (0.7 - 2.6) 
 
16 (30.8) 82 (30.6) 1.02 (0.5 - 2.1) 
 
               Seconday or 
tertiary education 
10 (14.7) 36 (14.3) 1.03 (0.5-2.2) 0.93 12 (23.1) 34 (12.7) 2.06 (1.0-4.3) 0.05 
               Employment 5 (7.3) 12 (4.8) 1.59 (0.5-4.7) 0.40 2 (3.9) 15 (5.6) 0.67 (0.1-3.1) 0.61 
History of current 
pregnancy 
                
Place of recruitment        
      
 
Antenatal clinic 36 (52.9) 164 (65.1) 1.00 
0.07 
25 (48.1) 175 (65.3) 1.00 0.02  
At delivery 32 (47.1) 88 (34.9) 1.66 (0.9 - 2.9) 27 (51.9) 93 (34.7) 2.03 (1.1-2.7)   
Gestational age at 
recruitment (weeks)  
(mean±SD)ˠ   
37.3 (±2.2) 37.0 (±1.9) 1.08 (0.9-1.2) 0.38 37.3 (±0.3) 37.0 (±0.1) 1.07 (0.9-1.2) 0.36 
At least 3 antenatal 
visits during the 
pregnancy 
37 (54.4) 128 (50.8) 1.39 (0.8-2.5) 0.29 29 (64.4) 136 (57.6) 1.33 (0.7-2.6) 0.40 
Gestational 
hypertension 
4 (5.9) 19 (7.5) 0.75 (0.2-2.3) 0.26 4 (8.0) 19 (7.2) 1.13 (0.4-3.5) 0.84 
Vaginal itching 2 (2.9) 19 (7.5) 0.37 (0.1 – 1.6) 0.17 4 (7.7) 17 (6.3) 1.23 (0.4 – 3.8) 0.13 
Vaginal discharge 22 (32.4) 103 (40.9) 0.69 (0.4-1.2) 0.20 14 (26.9) 111 (41.4) 0.52 (0.3-1.0) 0.05 
Urinary symptoms 0 (0.0) 3 (1.2) 0 (0.0) 0.37 1 (1.9) 2 (0.8) 2.61 (0.2-29.5) 0.42 
Antibiotic usageᶤ   3 (4.4) 10 (4.0)  1.07 (0.3 -4.0) 0.92 2 (3.8) 11 (4.1) 0.78 (0.2-2.9) 0.69 
  Investigations  
during pregnancy 
                
Syphilis positive 0 (0.0) 2 (0.8) 0 (0.0) 0.46 0 (0.0) 2 (0.8) 0 (0.0) 0.53 
HIV positive 26 (38.2) 91 (36.1) 1.09 (0.6-1.9) 0.75 18 (34.6) 99 (36.9) 0.90 (0.5-1.7) 0.75 
Anemiaʱ 38 (55.9) 168 (66.7) 0.65 (0.3-1.3) 0.21 25 (64.1) 181 (80.4) 0.43 (0.2-0.9) 0.02 
Antibodies anti-GBSᶿ 23 (71.9) 60 (68.2) 1.19 (0.5 - 2.9) 0.70 19 (70.4) 64 (68.8) 1.08 (0.4 - 2.8) 0.89 
GBS colonization NA NA NA   13 (25) 55 (20.5) 1.29 (0.6-2.6) 0.47 
E. coli colonization 13 (19.1) 39 (15.5) 1.29 (0.6-2.6) 0.52 NA NA NA   
  Outcome                  
Gestational age at 
birth  
      
 
      
 
Term newborn  62 (91.2) 228 (90.5) 1.00 
0.86 
46 (88.5) 244 (91.0) 1.00 0.56  
Pre term newborn 6 (8.8) 24 (9.5) 0.92 (0.4-2.3) 6 (11.5) 24 (9.0) 1.33 (0.5-3.4)   
Stillbirth  1 (1.4) 4 (1.6) 0.86 (0.1-7.9) 0.89 0 (0.0) 5 (2.4) 0 (0.0) 0.28 
Low birth weight 
(<2500g) 
4 (5.9) 27 (10.7) 0.52 (0.2-1.5) 0.24 7 (13.5) 24 (9.0) 1.58 (0.6-3.9) 0.31 
Infant hospitalized in 
the first 90 days after 
birthᶬ 
2 (3.4) 6 (3.0) 1.15 (0.2-5.9) 0.86 3 (6.1) 5 (2.4) 2.7 (0.6-11.9) 0.17 
Death after birthᶬ 1 (1.4) 6 (2.4) 0.57 (0.1-4.8) 0.60 0 (0.0) 7 (3.3) 0 (0.0) 0.19 
Table
ˠGestational age is presented as mean and SD. ᵟP-value was derived from Chi2 test for categorical variables and t-test for quantitative variables.ᶽData 
available for 260 women. ᶤAntibiotic usage two weeks before sample collection. Data available for 259 women.. ʱData available for 264 women. 
ᶿAntibodies results available for 120 women recruited at delivery; ᶬdata for 262 newborns 90 days after birth. 
 
Table 3.  Multivariate analysis of socio-demographic and clinical variables of women colonized by GBS. 
Risk factors for GBS colonization 
GBS positive  
n (%), N=68 
Adjusted OR 95% CI p-valueᶿ   
      Lower Upper   
Age in years         
 
< 21 21 (30.9) 1.00       
0.69  
  
22 to 29 24 (35.3) 1.26 0.65 2.56 
≥30 23 (33.8) 1.46 0.74 2.89 
Gestational age at recruitment 
(mean ±SD) 37.3 (±2.2) 
 
0.98 
 
0.81 
 
1.19 
 
0.82 
Place of recruitment           
Antenatal clinics 200 (62.5) 1.00       
Delivery ward 120 (37.5) 1.85 0.84 4.08 0.125 
      
                    ᶿP-value was derived from likelihood ratio test. 
Table
 
Table 4.  Multivariate analysis of socio-demographic and clinical variables of women colonized by E. coli. 
Risk factors for E.coli colonization 
 E. coli, n (%), 
N=52 
Adjusted OR 95% CI p-valueᶿ   
      Lower Upper   
Age in years         
 
< 21 18 (34.6) 1.00       
0.97  
  
22 to 29 18 (34.6) 0.99 0.47 2.06 
≥30 16 (30.8) 1.14 0.53 2.47 
Gestational age at recruitment 
(mean ±SD) 
 
37.3 (±0.3) 
 
0.88 
 
0.71 
 
1.10 
 
0.27 
               Seconday or tertiary education           
Negative 40 (76.9) 1.00     
 0.26 
Positive 12 (23.1) 1.58 0.71 3.49 
Place of recruitment           
Antenatal clinic 25 (48.1) 1.00     
 0.15 
At delivery 27 (51.9) 2.12 0.77 5.84 
Vaginal discharge           
No 38 (73.1) 1.00       
Yes 14 (26.9) 0.83 0.36 1.95 0.67 
Anemia          
No 14 (26.9) 1.00       
0.18  
  
Yes 25 (48.1) 0.49 0.23 1.05 
Unknown 13 (25.0) 0.77 0.31 1.91 
                         ᶿP-value was derived from likelihood ratio test.     
 
Table
4 admitted
at MDH
1 clinical 
sepsisˠ
29 newborns followed-
up 90 days after birth
0 sepsis
1 GBS 
sepsisʱ
1 clinical 
sepsisʶ
Exclusions
Exclusions
HOSPITAL
Antenatal clinics
233 women with gestational age ≥34 
weeks screened 
(June- September 2014)
Non-emancipated minors: 3
Living out of study area: 30
200 women with gestational age 
≥34 weeks recruited 
Delivery ward
858 deliveries 
(September 2014 – January 2015)
Non-emancipated minors: 19
Previously recruited in ANC: 196
Non optimal clinical condition to sign 
the IC: 22
Refusal to participate: 9
No time to explain study and sign IC 
before delivery: 56
Delivery out of working hours: 436
120 women regardless of 
gestational age recruited 
32 newborns born to 
GBS carriers
32 newborns born to 
GBS carriersᶤ
2 
newborn
s born to 
mothers 
receiving 
IAP
116 newborns 
followed-up 90 
days after birth
168 newborns born to 
non-GBS carriers
88 newborns born to  
non-GBS carriers
8 
newborns 
did not 
receive 
prophylaxis
22 
newborns 
received a 
single 
dose of 
penicillin
31 newborns 
followed-up 90 
days after birth
86 newborns 
followed-up 90 
days after birth
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SUPPLEMENTARY MATERIAL 
 
Table S1. Resistance profile of group B streptococcal and Escherichia coli isolates. 
Antimicrobial agents  GBS isolates, N=104  E.coli isolates, N=62 
  
Recto-vaginal, 
n(%), N=54 
Vaginal, n(%), 
N=50 
Vaginal, n(%), 
N=52 
Urine, n(%), 
N=10 
Penicillin         
Full resistant 0 (0) 0 (0) NA NA 
Intermediate resistant 0 (0) 0 (0) NA NA 
Ampicillin         
Full resistant 0 (0) 0 (0) 17 (32.7) 4 (40.0) 
Intermediate resistant 0 (0) 0 (0) 0 (0) 0 (0) 
Ceftriaxone         
Full resistant 0 (0) 0 (0) 0 (0) 0 (0) 
Intermediate resistant 0 (0) 0 (0) 1 (1.9) 1 (10.0) 
Chloramphenicol         
Full resistant 1 (1.9) 0 (0) 2 (3.9) 0 (0) 
Intermediate resistant 3 (5.6) 4(8.0) 0 (0) 0 (0) 
Erythromycin         
Full resistant 14 (25.9) 10(20.0) NA NA 
Intermediate resistant 4 (7.4) 6 (12.0) NA NA 
Clindamycin         
Full resistant  10 (18.5) 7 (14.0) NA NA 
Intermediate resistant 1 (1.9) 2 (4.0) NA NA 
Tetracycline         
Full resistant NA NA 15 (28.9) 2 (20.0) 
Intermediate resistant NA NA 0.50 2.16 
Vancomycine         
Full resistant 0 (0) 0 (0) NA NA 
Intermediate resistant 2 (3.7) 0 (0) NA NA 
Nalidixic acid         
Full resistant NA NA 3 (5.8) 3 (30.0) 
Intermediate resistant NA NA 1 (1.9) 0 (0.0) 
Amoxicillin/clavulanic acid         
Full resistant NA NA 11 (21.2) 1 (10.0) 
Intermediate resistant NA NA 0 (0) 0 (0) 
Cefuroxime         
Full resistant NA NA 1 (1.9) 1 (10.0) 
Intermediate resistant NA NA 0.50 2.16 
Cefoxitine         
Full resistant NA NA 0 (0) 0 (0) 
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Intermediate resistant NA NA 3 (5.8) 1 (10.0) 
Ceftazidime         
Full resistant NA NA 0 (0) 0 (0) 
Intermediate resistant NA NA 0 (0) 0 (0) 
Aztreonam         
Full resistant NA NA 1 (1.9) 1 (10.0) 
Intermediate resistant NA NA 0.50 2.16 
Piperacillin-Tazobactam         
Full resistant NA NA 0 (0) 0 (0) 
Intermediate resistant NA NA 0 (0) 0 (0) 
Ertapenem         
Full resistant NA NA 0 (0) 0 (0) 
Intermediate resistant NA NA 0 (0) 0 (0) 
Imipenem         
Full resistant NA NA 0 (0) 0 (0) 
Intermediate resistant NA NA 0 (0) 0 (0) 
Meropenem         
Full resistant NA NA 0 (0) 0 (0) 
Intermediate resistant NA NA 4 (7.7) 0 (0) 
Ciprofloxacine         
Full resistant NA NA 1(1.9) 2 (20.0) 
Intermediate resistant NA NA 1(1.9) 0 (0) 
Gentamicine         
Full resistant NA NA 2 (3.9) 0 (0) 
Intermediate resistant NA NA 0 (0) 0 (0) 
Trimethoprim/ sulfamethoxazole         
Full resistant NA NA 34 (65.4) 4 (40.0) 
Intermediate resistant NA NA 0.50 2.16 
Trobramicin         
Full resistant NA NA 1(1.9) 0 (0) 
Intermediate resistant NA NA 0 (0) 0 (0) 
     NA: not applicable 
 
 
 
 
 
 
 
Fig S1. Serotype distribution of vaginal and recto-vaginal GBS isolates 
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A )Serotype distribution of recto-vaginal isolates (53samples). B) Serotype distribution of vaginal isolates (48 samples). 
 
